var title_f21_38_22112="Apical 4 chamber Ca MV annulus";
var content_f21_38_22112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral annular calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view shows a marked degree of dense echoes at the mitral annulus, a result of mitral annular calcification (MAC). The mitral valve is not easily seen because it is obscured by the highly reflective MAC.",
"    <div class=\"footnotes\">",
"     L: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22112=[""].join("\n");
var outline_f21_38_22112=null;
var title_f21_38_22113="Fetal ovarian cyst";
var content_f21_38_22113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian cyst in female fetus at 34 weeks' gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal sonogram shows complex cystic mass (arrow) in left abdomen (s = stomach, b = bladder). Through-transmission is seen posterior to cyst. On follow-up scans (not shown), cyst size remained the same but hematoma in cyst decreased in size. Excision was performed when infant was 3 months old, and pathology revealed intrauterine ovarian torsion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Trop, I, Levine, D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22113=[""].join("\n");
var outline_f21_38_22113=null;
var title_f21_38_22114="Incidence of GBS in nonpregnant adults by race and age";
var content_f21_38_22114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 657px\">",
"   <div class=\"ttl\">",
"    Incidence of invasive group B streptococcal (GBS) disease among nonpregnant adults, by age (A) and by race (B), 1990-2007",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 637px; height: 651px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Skoff TH, Farley MM, Petit S, et al. Increasing Burden of Invasive Group B Streptococcal Disease in Non-Pregnant Adults, 1990-2007. Clin Infect Dis 2009; 49:85. By permission of the Infectious Diseases Society of America. Copyright &copy; 2013 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22114=[""].join("\n");
var outline_f21_38_22114=null;
var title_f21_38_22115="Radioactive plaque ther";
var content_f21_38_22115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Treatment of intraocular melanoma with ruthenium plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22115=[""].join("\n");
var outline_f21_38_22115=null;
var title_f21_38_22116="Hydroxyprogesterone caproate: Patient drug information";
var content_f21_38_22116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydroxyprogesterone caproate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=see_link\">",
"     see \"Hydroxyprogesterone caproate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/22/20836?source=see_link\">",
"     see \"Hydroxyprogesterone caproate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11507626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Makena&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11561984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It delays a baby's birth when it is too early.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11561914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3069443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydroxyprogesterone, castor oil, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3069461",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, high blood pressure, liver disease, liver tumor, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3069459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant with more than 1 baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3069460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11561916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11561987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11561918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad irritation where the shot was given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11561986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11561915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11561988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11561919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16453 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22116=[""].join("\n");
var outline_f21_38_22116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561984\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561914\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561916\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561987\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561918\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561986\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561915\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561988\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11561919\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/60/42948?source=related_link\">",
"      Hydroxyprogesterone caproate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/22/20836?source=related_link\">",
"      Hydroxyprogesterone caproate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_38_22117="Intracranial meningioma";
var content_f21_38_22117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracranial meningioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 70 year-old woman presented with a several-week history of confusion. Panels (A, B): Non-contrast and contrast-enhanced head CT shows a large bifrontal lesion with calcifications and surrounding edema. Panels (C, D): Non-contrast and contrast-enhanced T1-weighted axial MR images of the head also demonstrate large flow voids representing blood vessels in the center of the tumor. Panel (E): Non-contrast T1-weighted sagittal MR image. Panel (F): Contrast-enhanced T1-weighted coronal MR image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Park, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22117=[""].join("\n");
var outline_f21_38_22117=null;
var title_f21_38_22118="Liotrix: Pediatric drug information";
var content_f21_38_22118=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"21\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liotrix: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38917?source=see_link\">",
"    see \"Liotrix: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/14/27877?source=see_link\">",
"    see \"Liotrix: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1022260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Thyroid Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F14856054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be adjusted based on clinical response and laboratory parameters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Congenital hypothyroidism: Note:",
"     </b>",
"     AAP recommends levothyroxine as the preferred treatment for hypothyroidism in neonates (AAP, 2006). Neonates should have therapy initiated at full doses. Oral: Usual daily dosage range: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): 3.1-6.25 mcg; levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 12.5-25 mcg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1022287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38917?source=see_link\">",
"      see \"Liotrix: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be adjusted based on clinical response and laboratory parameters",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Congenital hypothyroidism:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Infants should have therapy initiated at full doses. Oral: Usual daily dosage range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 1-6 months: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): 3.1-6.25 mcg/levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 12.5-25 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;6-12 months: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): 6.25-9.35 mcg/levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 25-37.5 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-5 years: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): 9.35-12.5 mcg/levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 37.5-50 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): 12.5-18.75 mcg/levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 50-75 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Typical doses &gt; Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): 18.75 mcg; levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 75 mcg once daily",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Oral: Initial: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ) 6.25 mcg/levothyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ) 25 mcg once daily; may increase by liothyronine 3.1 mcg/levothyroxine 12.5 mcg every 2-3 weeks. A lower initial dose (liothyronine 3.1 mcg/levothyroxine 12.5 mcg) is recommended in patients with long-standing myxedema, especially if cardiovascular impairment coexists. If angina occurs, reduce dose (usual maintenance dose: Liothyronine 12.5-25 mcg/levothyroxine 50-100 mcg)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     [levothyroxine sodium 12.5 mcg and liothyronine sodium 3.1 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     [levothyroxine sodium 25 mcg and liothyronine sodium 6.25 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;: 1 [levothyroxine sodium 50 mcg and liothyronine sodium 12.5 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;: 2 [levothyroxine sodium 100 mcg and liothyronine sodium 25 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;: 3 [levothyroxine sodium 150 mcg and liothyronine sodium 37.5 mcg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1022277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1022261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement or supplemental therapy in hypothyroidism of any etiology (FDA approved in all ages); pituitary TSH suppressant for the prevention or treatment of various types of euthyroid goiter, thyroid nodules, thyroiditis (Hashimoto&rsquo;s), multinodular goiter, and thyroid cancer (FDA approved in adults); diagnostic agent in suppression tests to diagnose suspected mild hyperthyroidism or to demonstrate thyroid gland autonomy (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for treatment of transient hypothyroidism associated with subacute thyroiditis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Liotrix may be confused with Klotrix&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thyrolar&reg; may be confused with Thyrogen&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F189146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased, cardiac arrhythmia, chest pain, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, fever, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, hyperhydrosis, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Changes in menstrual cycle, increased appetite, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hand tremor, myalgia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic skin reactions (rare), diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1022265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to liotrix or any component; untreated thyrotoxicosis, uncorrected adrenal insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14855960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Use with extreme caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease. Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated. Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated. May cause transient alopecia in children during first few months of therapy. In neonates and infants, cardiac overload, arrhythmias, and aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1022266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Not for use in the treatment of obesity or for weight loss",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; in euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction; larger doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs (sympathomimetic amines). Should not be used for treatment of infertility without unrelated hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liotrix has not been found to increase the risk of adverse effects following maternal use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1022292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     , TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T",
"     <sub>",
"      4",
"     </sub>",
"     remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T",
"     <sub>",
"      4",
"     </sub>",
"     is needed to evaluate further increase in dosage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T",
"     <sub>",
"      4",
"     </sub>",
"     . During the first 3 years of life, total- or free-T",
"     <sub>",
"      4",
"     </sub>",
"     should be maintained in the upper",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the normal range; this should result in normalization of TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of",
"     <i>",
"      in utero",
"     </i>",
"     hypothyroidism. Monitor closely for cardiac overload, arrhythmias, and aspiration from avid suckling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth, and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation, accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Suggested frequency for monitoring thyroid function tests: Every 1-2 months during the first year of life, every 2-3 months between ages 1-3 years, and every 3-12 months thereafter until growth is completed; repeat tests 2 weeks after any change in dosage.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1022280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Thyroid Function Tests",
"     </caption>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Lab Parameters",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          4",
"         </sub>",
"         (thyroxine) serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.1-20.9 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-14 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.8-16.6 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 month to 1 year",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.5-16.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1 year",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.0-12.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         Free thyroxine index (FTI)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.3-26.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 weeks",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.6-20.8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.4-17.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-12 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.1-14.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-6 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.7-13.3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;6 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.8-14.0",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"         serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Newborns",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-470 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-5 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-260 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90-240 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 years to Adult",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70-210 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"         uptake",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35%-45%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         TSH serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cord",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-22 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;40 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;25 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0-10 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1022279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liotrix is a uniform mixture of T",
"     <sub>",
"      4",
"     </sub>",
"     :T",
"     <sub>",
"      3",
"     </sub>",
"     in 4:1 ratio by weight. The primary active compound is T",
"     <sub>",
"      3",
"     </sub>",
"     (triiodothyronine), which may be converted from T",
"     <sub>",
"      4",
"     </sub>",
"     (thyroxine) and then circulates throughout the body to influence growth and maturation of various tissues. The exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores and stimulates protein synthesis, increases basal metabolic rate.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14855989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: T",
"     <sub>",
"      3",
"     </sub>",
"     : ~3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1022281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: T",
"     <sub>",
"      4",
"     </sub>",
"     : 40% to 80%; T",
"     <sub>",
"      3",
"     </sub>",
"     : 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: T",
"     <sub>",
"      4",
"     </sub>",
"     : &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to triiodothyronine (active); ~80% T",
"     <sub>",
"      4",
"     </sub>",
"     deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     : Euthyroid: 6-7 days; Hyperthyroid: 3-4 days; Hypothyroid: 9-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      3",
"     </sub>",
"     : 2.5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: T",
"     <sub>",
"      4",
"     </sub>",
"     : 2-4 hours; T",
"     <sub>",
"      3",
"     </sub>",
"     : 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (major route of elimination); partially feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1022293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/14/27877?source=see_link\">",
"      see \"Liotrix: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not change brands without physician's knowledge; thyroid replacement therapy is generally for life. Take in the morning before breakfast on an empty stomach. Do not take antacids or iron preparations within 4 hours of thyroid medication. Patients with diabetes should monitor their glucose levels (may increase need for oral hypoglycemics or insulin). Report chest pain, rapid heart rate, palpitations, heat intolerance, excessive sweating, increased nervousness, agitation, or lethargy.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1022294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Equivalent doses: The following statement on relative potency of thyroid products is included in a joint statement by American Thyroid Association (ATA), American Association of Clinical Endocrinologists (AACE) and The Endocrine Society (TES): For purposes of conversion, levothyroxine sodium (T",
"     <sub>",
"      4",
"     </sub>",
"     ) 100 mcg is usually considered equivalent to desiccated thyroid 60 mg, thyroglobulin 60 mg, or liothyronine sodium (T",
"     <sub>",
"      3",
"     </sub>",
"     ) 25 mcg. However, these are rough guidelines only and do not obviate the careful re-evaluation of a patient when switching thyroid hormone preparations, including a change from one brand of levothyroxine to another. Joint position statement is available at file://www.thyroid.org/professionals/advocacy/04_12_08_thyroxine.html.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al, \"Update of Newborn Screening and Therapy for Congenital Hypothyroidism,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(6):2290-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/38/22118/abstract-text/16740880/pubmed\" id=\"16740880\" target=\"_blank\">",
"        16740880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87041 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22118=[""].join("\n");
var outline_f21_38_22118=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709014\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189131\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189132\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022260\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856054\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022287\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189112\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189095\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022277\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022261\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189147\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189146\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022265\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855960\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022266\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299608\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189104\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189107\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189120\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022292\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022280\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022279\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855989\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022281\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022293\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022294\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87041|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38917?source=related_link\">",
"      Liotrix: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/14/27877?source=related_link\">",
"      Liotrix: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_38_22119="Thyrotoxic periodic paralysis";
var content_f21_38_22119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyrotoxic periodic paralysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22119/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22119/contributors\">",
"     Laurie Gutmann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22119/contributors\">",
"     Robin Conwit, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22119/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22119/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/38/22119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic paralysis (PP) is a muscle disease in the family of diseases called channelopathies, manifested by episodes of painless muscle weakness. These episodes may be precipitated by heavy exercise, fasting, or high-carbohydrate meals. PP is classified as hypokalemic when episodes occur in association with low potassium blood levels or as hyperkalemic when episodes can be induced by elevated potassium. Most cases of PP are hereditary, usually with an autosomal dominant inheritance pattern. Acquired cases of hypokalemic PP have been described in association with hyperthyroidism. The clinical features of these disorders are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef65215 \" href=\"UTD.htm?13/14/13549\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to other forms of thyroid disease, which are more common in women, thyrotoxic PP is much more frequently seen in males; the prevalence of thyrotoxic PP is also highest in Asians. This diagnosis should be considered when this demographic of patients presents with marked painless weakness after provocation with exercise or changes in diet.",
"   </p>",
"   <p>",
"    Thyrotoxic PP will be reviewed here. Other causes of PP and other neurologic manifestations of thyrotoxicosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link\">",
"     \"Hypokalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyrotoxic PP is a sporadic form of hypokalemic PP that may occur in association with hyperthyroidism. This contrasts with familial hypokalemic PP which has an autosomal dominant inheritance.",
"   </p>",
"   <p>",
"    Any etiology of hyperthyroidism, including thyroxine abuse, can be associated with thyrotoxic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Graves' disease is the underlying disorder in most cases of thyrotoxic PP, as it is in most cases of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyrotoxic PP has been most widely reported and studied in Asian populations, in which the incidence among patients with hyperthyroidism is approximately 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This contrasts with non-Asian populations, in which the incidence of thyrotoxic PP among individuals with hyperthyroidism is estimated to be 0.1 to 0.2 percent. A New Zealand study found that Polynesians were also at higher risk for thyrotoxic PP compared to those of European descent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite a higher incidence of hyperthyroidism in women, over 95 percent of thyrotoxic PP cases occur in men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Thus, the incidence of thyrotoxic PP is particularly high among Asian men with thyrotoxicosis (8.7 to 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which hyperthyroidism can produce hypokalemic PP is not well understood. Thyroid hormone increases tissue responsiveness to beta-adrenergic stimulation, which, along with thyroid hormone, increases sodium-potassium ATPase activity on the skeletal muscle membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/15\">",
"     15",
"    </a>",
"    ]. This tends to drive potassium into cells, perhaps leading to hyperpolarization of the muscle membrane and relative inexcitability of the muscle fibers. Thyrotoxic patients with PP have been found to have higher sodium pump activity than those without paralytic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. In this way, excess thyroid hormone may predispose to paralytic episodes by increasing the susceptibility to the hypokalemic action of epinephrine or insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/8,17\">",
"     8,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin resistance with compensatory hyperinsulinemia is suspected to have a role in the pathogenesis of thyrotoxic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In one study, patients with a history of thyrotoxic PP were heavier and exhibited reduced insulin sensitivity compared with patients with thyrotoxicosis without thyrotoxic PP. Insulin also activates the sodium-potassium ATPase pump and may act synergistically with thyroid hormone to drive potassium into cells. This is consistent with the observation that a heavy meal can be a precipitant for attacks of thyrotoxic PP.",
"   </p>",
"   <p>",
"    While patients with thyrotoxic PP do not have the genetic mutations associated with familial hypokalemic PP, it has been suggested that individuals who are susceptible to thyrotoxic PP may have an ion channel defect, which, in the euthyroid state, is not sufficient to produce symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/6,20-24\">",
"     6,20-24",
"    </a>",
"    ]. One study revealed that 10 of 30 Caucasian or Brazilian patients with thyrotoxic PP had a mutation in the gene encoding Kir2.6, an inwardly rectifying potassium channel, expressed in skeletal muscle that is transcriptionally regulated by thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/25\">",
"     25",
"    </a>",
"    ]. These mutations were also seen in 26 percent of 26 thyrotoxic PP patients from Singapore, but only in 1 of 114 patients from Hong Kong or Thailand.",
"   </p>",
"   <p>",
"    Other predisposing genetic traits have been suggested. One study comparing DNA analysis in 50 patients with thyrotoxic PP to 50 patients with hyperthyroidism but no PP suggested an association between single nucleotide polymorphisms in intron 3 of the gene encoding the alpha3 subunit of the GABA receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A role for testosterone in the pathogenesis for thyrotoxic PP is suggested by the predominance of this condition in men, and the demonstration that testosterone increases sodium-potassium ATPase activity in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all the periodic paralyses, attacks of weakness occur suddenly with generalized weakness and preserved consciousness. The age of onset of symptoms in thyrotoxic PP is between 20 and 39 years in approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/8,12,13,15,30-32\">",
"     8,12,13,15,30-32",
"    </a>",
"    ]. Although this later age of onset is helpful to distinguish thyrotoxic PP from the familial periodic paralyses, which present at a younger age, adolescents with thyrotoxic PP have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/21,33\">",
"     21,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many patients, clinical features of hyperthyroidism precede the onset of PP by months or even years, but they have been noted to occur at the same time (in 43 to 60 percent of patients) or following the development of PP (in 11 to 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/8,11,14,15,31,32,34\">",
"     8,11,14,15,31,32,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic examination during an attack demonstrates weakness, usually affecting proximal more than distal muscles, and the legs more than the arms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/2,12,30,31,35\">",
"     2,12,30,31,35",
"    </a>",
"    ]. Mild myalgia is a complaint in less than half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/12\">",
"     12",
"    </a>",
"    ]. Decreased muscle tone with hyporeflexia or areflexia is typical, although normal or hyperactive reflexes may be observed. In one series, tachycardia (mean heart rate = 105 bpm) was noted at presentation and distinguished these patients from those with familial hypokalemic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/34\">",
"     34",
"    </a>",
"    ]. Exceptional cases of bulbar weakness and respiratory weakness requiring ventilatory support have been reported in thyrotoxic PP, as well as cases of severe, even fatal, arrhythmias (sinus arrest, second degree atrioventricular [AV] block, ventricular fibrillation, and ventricular tachycardia) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/5,36-39\">",
"     5,36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attacks vary in frequency and duration. Intervals of weeks to months are common, but some patients experience several attacks per week [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/12,35\">",
"     12,35",
"    </a>",
"    ]. A duration of symptoms of several hours is typical, but can range from minutes to days. As with hypokalemic PP, attacks in thyrotoxic PP can be precipitated by events that are associated with an increased release of epinephrine or insulin, both of which cause movement of potassium into cells and low potassium blood levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. Most commonly, the inciting event is either rest after strenuous physical activity, stress, or a high-carbohydrate load. Other events reported to induce attacks in thyrotoxic PP include cold exposure, infection, alcohol intake, pulse corticosteroid therapy, and menses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/8,32,40-42\">",
"     8,32,40-42",
"    </a>",
"    ]. In many instances, no obvious precipitant is identified. Although attacks of weakness may occur at any time of the day, a high frequency of attacks at night or early in the morning has been reported in thyrotoxic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/5\">",
"     5",
"    </a>",
"    ]. A seasonal variation has also been suggested, with more frequent attacks in summer months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of hypokalemia during an attack is variable; in one series of 78 patients the mean serum potassium level was 2.1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/30\">",
"     30",
"    </a>",
"    ]. Cases with extremely low potassium levels &lt;1.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    are frequently reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/2,5,12,31,36-38,43\">",
"     2,5,12,31,36-38,43",
"    </a>",
"    ]. However, in at least two cases of periodic paralysis attributed to thyrotoxic PP, the ictal potassium level was normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/12,44,45\">",
"     12,44,45",
"    </a>",
"    ]. Usually, the severity of weakness corresponds to the degree of hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with thyrotoxic PP, by definition, have attacks in the hyperthyroid state. Supporting laboratory findings include elevation of serum thyroxine (T4) and low thyrotropin levels (TSH). Patients with elevated T3 and normal T4 levels have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other common laboratory findings include mild hypophosphatemia and hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/5,31,32\">",
"     5,31,32",
"    </a>",
"    ]. These findings may help distinguish thyrotoxic PP from familial hypokalemic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/34,35,47\">",
"     34,35,47",
"    </a>",
"    ]. In one study, a urine calcium to phosphate ratio of higher than 1.7 was a sensitive and specific test to distinguishing thyrotoxic PP from familial hypokalemic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/48\">",
"     48",
"    </a>",
"    ]. Creatine kinase may be normal but has been reported to be mildly elevated in two-thirds of patients, and rhabdomyolysis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrocardiogram (ECG) changes are common in an attack of thyrotoxic PP. These include those findings consistent with hypokalemia: ST depression, sinus tachycardia, U waves (",
"    <a class=\"graphic graphic_waveform graphicRef73888 \" href=\"UTD.htm?18/38/19043\">",
"     waveform 1",
"    </a>",
"    ), as well as an elevated higher heart rate, abnormal PR interval, higher QRS voltage, and first degree AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/43\">",
"     43",
"    </a>",
"    ]. The latter ECG findings are more common in patients with thyrotoxic PP as compared to patients with familial hypokalemic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/47\">",
"     47",
"    </a>",
"    ]. Severe arrhythmias (eg, sinus arrest, second degree atrioventricular [AV] block, ventricular fibrillation, and ventricular tachycardia) are not common but are described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an acute attack, thyrotoxic PP must be distinguished from other causes of acute quadriparesis, such as myasthenic crisis, Guillain-Barr&eacute; syndrome, acute myelopathy (eg, transverse myelitis), tick paralysis, and botulism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The finding of hypokalemia generally alerts the clinician to the diagnosis of periodic paralysis, in which the possibility of thyrotoxicosis must always be evaluated, particularly in the absence of a family history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .) After a thyrotoxic state is established, the patient is further evaluated to determine the underlying cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of electromyography, provocative testing, and muscle biopsy are similar to those seen in familial hypokalemic PP, but these tests are often unnecessary (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link&amp;anchor=H6#H6\">",
"     \"Hypokalemic periodic paralysis\", section on 'Diagnosis'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If thyrotoxicosis is not established as the cause, an electrocardiogram (ECG) should be performed to identify a prolonged QT or QU interval suggestive of Andersen syndrome (",
"    <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"UTD.htm?26/24/27008\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link&amp;anchor=H14#H14\">",
"     \"Hypokalemic periodic paralysis\", section on 'Andersen syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUTE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with familial hypokalemic PP, potassium supplementation may lead to improvement of weakness. One prospective study compared treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    to normal saline infusion and found a shorter recovery time with use of potassium (6.3 versus 13.5 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/49\">",
"     49",
"    </a>",
"    ]. In a retrospective case series, patients who received intravenous potassium recovered more quickly than those who received oral supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/45\">",
"     45",
"    </a>",
"    ]. There may be a delayed response of a few hours following potassium administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/38\">",
"     38",
"    </a>",
"    ]. Required doses of potassium supplementation are variable and range from 10 to 200 mEq [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/2,5,30\">",
"     2,5,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rebound hyperkalemia appears to be a prominent problem in thyrotoxic PP, occurring in approximately 40 to 59 percent of treated attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/5,30,31\">",
"     5,30,31",
"    </a>",
"    ]. In one study, eighty percent of patients who developed rebound hyperkalemia had received greater than 90 meq of potassium within 24 hours. This has led to a suggested protocol of 30 mEq of oral potassium every two hours until improvement begins, with a maximum dose of 90 mEq in 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/50\">",
"     50",
"    </a>",
"    ]. Some recommend even slower rates of administration (&lt;10 mEq per hour) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/2,49\">",
"     2,49",
"    </a>",
"    ]. In one case series, a fall in serum potassium occurred during initial treatment in one-fourth of patients; these patients also had higher free thyroxine levels, ultimately required higher doses of potassium supplementation, and were more likely to have severe rebound hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Close monitoring of serum potassium is essential, and cardiac monitoring is recommended for all patients during treatment and observation. A cardiology consultation should be obtained for severe",
"    <span class=\"nowrap\">",
"     arrhythmias/ECG",
"    </span>",
"    changes. Correction of hypomagnesemia if present is also recommended.",
"   </p>",
"   <p>",
"    Replacement of potassium may be insufficient to resolve an attack. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    has been reported to reverse weakness and hypokalemia in patients with thyrotoxic PP that is unresponsive to potassium administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/38,40,51,52\">",
"     38,40,51,52",
"    </a>",
"    ]. These patients received doses of 1 mg of intravenous propranolol every 10 minutes up to a maximum dose of 3 mg. In one report, oral propranolol (3",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    administered without potassium supplementation reversed both weakness and hypokalemia in two patients with an acute attack of thyrotoxic PP without inducing rebound hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/17\">",
"     17",
"    </a>",
"    ]. Propranolol, a beta adrenergic blocker, presumably reverses the excessive stimulation of the sodium-potassium ATPase and excessive drive of potassium into cells (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of euthyroidism eliminates attacks of thyrotoxic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/8,53\">",
"     8,53",
"    </a>",
"    ]. When patients become euthyroid, the electromyography (EMG) exercise test normalizes, and attacks are no longer inducible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/54\">",
"     54",
"    </a>",
"    ]. Thyrotoxic PP can reemerge if thyrotoxicosis recurs. The management of hyperthyroidism differs according to the underlying etiology.",
"   </p>",
"   <p>",
"    The administration of beta-blocking medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (40 to 120 mg daily) with or without potassium supplementation has also been shown to decrease the frequency and severity of attacks, and may be used as a temporizing measure until a euthyroid state is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/15,17,46,51,55,56\">",
"     15,17,46,51,55,56",
"    </a>",
"    ]. A nonselective beta blocker (eg, propranolol) should be given; beta-1 selective agents are less likely to inhibit the beta-2 receptor-mediated hypokalemic effect of epinephrine and may therefore be less likely to prevent paralytic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to familial hypokalemic PP, carbonic anhydrase inhibitors have not been shown to be of benefit in thyrotoxic PP and may even increase the frequency of attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/57\">",
"     57",
"    </a>",
"    ]. Potassium supplementation is not effective as prophylaxis in thyrotoxic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22119/abstract/6\">",
"     6",
"    </a>",
"    ]. As with hypokalemic PP, precipitating factors, such as heavy exercise, high-carbohydrate diets, and alcohol, should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=see_link\">",
"       \"Patient information: Periodic paralysis syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyrotoxic periodic paralysis (PP) represents an acquired form of hypokalemic PP, in which attacks of generalized weakness occur, often precipitated by rest after strenuous exercise or a high-carbohydrate load.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyrotoxic PP is more prevalent in Asians than in non-Asians and also in males more than in females. Any cause of hyperthyroidism can be associated with thyrotoxic PP. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The distinguishing clinical features of hypokalemic, thyrotoxic, and hyperkalemic periodic paralysis, and the Andersen syndrome are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef65215 \" href=\"UTD.htm?13/14/13549\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of thyrotoxic PP is made when a patient presents with a paralytic attack that is associated with hypokalemia and hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of an acute attack of thyrotoxic PP with severe weakness, we recommend administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients should be on cardiac monitoring, and potassium levels should be monitored for potential rebound hyperkalemia for 24 hours. A suggested protocol is potassium 30 mEq every two hours, with a maximum dose of 90 mEq in 24 hours. Oral administration, if possible, is preferred. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For acute weakness, which is not responding to potassium administration, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      (1 mg IV or 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attacks of periodic paralysis will cease with return to euthyroid state. Interim measures to ameliorate attacks include avoiding strenuous exercise and high-carbohydrate loads. If attacks continue to be problematic, we recommend prophylactic use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      until euthyroidism is achieved (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Preventive treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/1\">",
"      Chen YC, Fang JT, Chang CT, Chou HH. Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. Ren Fail 2001; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/2\">",
"      Pompeo A, Nepa A, Maddestra M, et al. Thyrotoxic hypokalemic periodic paralysis: An overlooked pathology in western countries. Eur J Intern Med 2007; 18:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/3\">",
"      Hannon MJ, Behan LA, Agha A. Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement in a Caucasian man. Ann Clin Biochem 2009; 46:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/4\">",
"      Chou HK, Tsao YT, Lin SH. An unusual cause of thyrotoxic periodic paralysis: triiodothyronine-containing weight reducing agents. Am J Med Sci 2009; 337:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/5\">",
"      Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med 1999; 159:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/6\">",
"      Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab 2006; 91:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/7\">",
"      Pothiwala P, Levine SN. Analytic review: thyrotoxic periodic paralysis: a review. J Intensive Care Med 2010; 25:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/8\">",
"      Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore) 1992; 71:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/9\">",
"      Kelley DE, Gharib H, Kennedy FP, et al. Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. Arch Intern Med 1989; 149:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/10\">",
"      Elston MS, Orr-Walker BJ, Dissanayake AM, Conaglen JV. Thyrotoxic, hypokalaemic periodic paralysis: Polynesians, an ethnic group at risk. Intern Med J 2007; 37:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/11\">",
"      Ko GT, Chow CC, Yeung VT, et al. Thyrotoxic periodic paralysis in a Chinese population. QJM 1996; 89:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/12\">",
"      Hsieh MJ, Lyu RK, Chang WN, et al. Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol 2008; 15:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/13\">",
"      OKINAKA S, SHIZUME K, IINO S, et al. The association of periodic paralysis and hyperthyroidism in Japan. J Clin Endocrinol Metab 1957; 17:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/14\">",
"      McFadzean AJ, Yeung R. Periodic paralysis complicating thyrotoxicosis in Chinese. Br Med J 1967; 1:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/15\">",
"      Rhee. N Engl J Med 2012; 366:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/16\">",
"      Chan A, Shinde R, Chow CC, et al. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ 1991; 303:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/17\">",
"      Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis 2001; 37:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/18\">",
"      Soonthornpun S, Setasuban W, Thamprasit A. Insulin resistance in subjects with a history of thyrotoxic periodic paralysis (TPP). Clin Endocrinol (Oxf) 2009; 70:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/19\">",
"      Chan A, Shinde R, Chow CC, et al. Hyperinsulinaemia and Na+, K(+)-ATPase activity in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf) 1994; 41:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/20\">",
"      Fontaine B, Lapie P, Plassart E, et al. Periodic paralysis and voltage-gated ion channels. Kidney Int 1996; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/21\">",
"      Schalin-Jantti C, Laine T, Valli-Jaakola K, et al. Manifestation, management and molecular analysis of candidate genes in two rare cases of thyrotoxic hypokalemic periodic paralysis. Horm Res 2005; 63:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/22\">",
"      Vendrame F, Verrienti A, Parlapiano C, et al. Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Ann Clin Biochem 2008; 45:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/23\">",
"      Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab 2002; 87:4881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/24\">",
"      Arimura K, Arimura Y, Ng AR, et al. Muscle membrane excitability after exercise in thyrotoxic periodic paralysis and thyrotoxicosis without periodic paralysis. Muscle Nerve 2007; 36:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/25\">",
"      Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010; 140:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/26\">",
"      Jongjaroenprasert W, Chanprasertyotin S, Butadej S, et al. Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population. Clin Endocrinol (Oxf) 2008; 68:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/27\">",
"      Kurihara K, Maruyama S, Hosoi K, et al. Regulation of Na+,K+-ATPase in submandibular glands of hypophysectomized male mice by steroid and thyroid hormones. J Histochem Cytochem 1996; 44:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/28\">",
"      Tran HA, Reeves GE. Hepatitis C infection and thyrotoxic periodic paralysis--a novel use of an old drug. Am J Med Sci 2008; 336:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/29\">",
"      Guerra M, Rodriguez del Castillo A, Battaner E, Mas M. Androgens stimulate preoptic area Na+,K+-ATPase activity in male rats. Neurosci Lett 1987; 78:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/30\">",
"      Shiang JC, Cheng CJ, Tsai MK, et al. Therapeutic analysis in Chinese patients with thyrotoxic periodic paralysis over 6 years. Eur J Endocrinol 2009; 161:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/31\">",
"      Li J, Yang XB, Zhao Y. Thyrotoxic periodic paralysis in the Chinese population: clinical features in 45 cases. Exp Clin Endocrinol Diabetes 2010; 118:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/32\">",
"      Wong P. Hypokalemic thyrotoxic periodic paralysis: a case series. CJEM 2003; 5:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/33\">",
"      Wong GW, Leung TF, Lo AF, et al. Thyrotoxic periodic paralysis in a 14-year-old boy. Eur J Pediatr 2000; 159:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/34\">",
"      Lin SH, Lin YF, Halperin ML. Hypokalaemia and paralysis. QJM 2001; 94:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/35\">",
"      Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006; 129:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/36\">",
"      Liu YC, Tsai WS, Chau T, Lin SH. Acute hypercapnic respiratory failure due to thyrotoxic periodic paralysis. Am J Med Sci 2004; 327:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/37\">",
"      Wu CZ, Wu YK, Lin JD, Kuo SW. Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia. Thyroid 2008; 18:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/38\">",
"      Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med 2004; 26:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/39\">",
"      Loh KC, Pinheiro L, Ng KS. Thyrotoxic periodic paralysis complicated by near-fatal ventricular arrhythmias. Singapore Med J 2005; 46:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/40\">",
"      Yu TS, Tseng CF, Chuang YY, et al. Potassium chloride supplementation alone may not improve hypokalemia in thyrotoxic hypokalemic periodic paralysis. J Emerg Med 2007; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/41\">",
"      Hagel S, Elznerova T, Dietrich W, et al. Chest pain and paralysis after pulse prednisolone therapy an unusual case presentation of thyrotoxic periodic paralysis: a case report. Cases J 2009; 2:7501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/42\">",
"      Wongraoprasert S, Buranasupkajorn P, Sridama V, Snabboon T. Thyrotoxic periodic paralysis induced by pulse methylprednisolone. Intern Med 2007; 46:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/43\">",
"      Goldberger ZD. Images in cardiovascular medicine. An electrocardiogram triad in thyrotoxic hypokalemic periodic paralysis. Circulation 2007; 115:e179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/44\">",
"      Wu CC, Chau T, Chang CJ, Lin SH. An unrecognized cause of paralysis in ED: thyrotoxic normokalemic periodic paralysis. Am J Emerg Med 2003; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/45\">",
"      Cesur M, Bayram F, Temel MA, et al. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series. Clin Endocrinol (Oxf) 2008; 68:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/46\">",
"      Griggs RC, Bender AN, Tawil R. A puzzling case of periodic paralysis. Muscle Nerve 1996; 19:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/47\">",
"      Hsu YJ, Lin YF, Chau T, et al. Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. Am J Med Sci 2003; 326:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/48\">",
"      Lin SH, Chu P, Cheng CJ, et al. Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio. Crit Care Med 2006; 34:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/49\">",
"      Lu KC, Hsu YJ, Chiu JS, et al. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med 2004; 22:544.",
"     </a>",
"    </li>",
"    <li>",
"     Yeo, PPB, Lee, KO, Cheah, JS. Thyrotoxic periodic paralysis: a study of 51 patients. In: Proceedings of the Second Congress of the Association of Southeast Asian Nations (ASEAN) Federation of Endocrine Societies, Nov 30 - Dec 3, Bangkok, Thailand 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/51\">",
"      Shayne P, Hart A. Thyrotoxic periodic paralysis terminated with intravenous propranolol. Ann Emerg Med 1994; 24:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/52\">",
"      Birkhahn RH, Gaeta TJ, Melniker L. Thyrotoxic periodic paralysis and intravenous propranolol in the emergency setting. J Emerg Med 2000; 18:199.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. linical Physiology of Acid-Base and Electrolyte Disorders, 5th, McGraw-Hill, New York 2001. p.836.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/54\">",
"      Jackson CE, Barohn RJ. Improvement of the exercise test after therapy in thyrotoxic periodic paralysis. Muscle Nerve 1992; 15:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/55\">",
"      Yeung RT, Tse TF. Thyrotoxic periodic paralysis. Effect of propranolol. Am J Med 1974; 57:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/56\">",
"      Conway MJ, Seibel JA, Eaton P. Thyrotoxicosis and periodic paralysis: improvement with beta blockade. Ann Intern Med 1974; 81:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22119/abstract/57\">",
"      Pt&aacute;cek L. The familial periodic paralyses and nondystrophic myotonias. Am J Med 1998; 105:58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5154 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22119=[""].join("\n");
var outline_f21_38_22119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUTE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5154|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/14/13549\" title=\"table 1\">",
"      Periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5154|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?18/38/19043\" title=\"waveform 1\">",
"      Hypokalemia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/24/27008\" title=\"waveform 2\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=related_link\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=related_link\">",
"      Patient information: Periodic paralysis syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_38_22120="Operative mortality after coronary artery bypass graft surgery";
var content_f21_38_22120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Operative mortality after coronary artery bypass graft surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Sary Aranki, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22120/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/38/22120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of coronary heart disease (CHD) has evolved significantly due in part to improvements in both medical therapy and surgical and percutaneous revascularization techniques. The majority of patients with chronic stable angina are treated with medical therapy, but there are a variety of indications for coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The perioperative and in-hospital mortality rate after CABG will be reviewed here. Cardiac and noncardiac complications of CABG and the long-term outcome after CABG are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=see_link\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PREVENTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on bypass surgery issued general recommendations for preventive measures to minimize the risk of both morbidity and mortality after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      to improve morbidity and mortality",
"     </li>",
"     <li>",
"      Beta blockers to prevent perioperative atrial fibrillation;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      are alternatives",
"     </li>",
"     <li>",
"      Statin therapy",
"     </li>",
"     <li>",
"      Prophylactic antimicrobials to prevent surgical site infection",
"     </li>",
"     <li>",
"      Strict glycemic control (using an insulin infusion) during the perioperative period, which also may reduce sternal wound infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, an antifibrinolytic agent is now used in most CABG procedures to minimize bleeding.",
"   </p>",
"   <p>",
"    The evidence supporting the efficacy of these therapies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link&amp;anchor=H13#H13\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Prevention of AF and complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to these medical therapies, carotid duplex ultrasound may be performed to identify severe carotid stenosis in patients with an audible bruit, severe peripheral artery disease, or a previous stroke or transient ischemic attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2168?source=see_link\">",
"     \"Prevention of neurologic complications of cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OPERATIVE MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using registry data in the United States, the perioperative and in-hospital mortality rate after CABG between 1997 and 2001 averaged about 1 percent for the lowest risk elective patients, and 2 to 5 percent for all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, the risk is highly dependent upon comorbid disease, postoperative complications, and the hospital volume of CABG procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Patients who undergo CABG at low volume centers are more likely to be at high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/5\">",
"     5",
"    </a>",
"    ], while patients who undergo CABG at high volume centers are more likely to be at low risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These mortality rates are probably not applicable to all countries. This was illustrated in a report from the National Health Service in Brazil in which the perioperative mortality was 7.0 percent in almost 66,000 CABG procedures performed between 2000 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/7\">",
"     7",
"    </a>",
"    ]. Possible contributors to this increase in risk are bias (some of the American registries are voluntary and therefore may underestimate events) and a greater number of cases performed in low volume hospitals. The difference in outcomes may affect clinical decision making on the indications for CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREDICTORS OF RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of preoperative and intraoperative factors have been demonstrated to influence the rate of operative mortality after CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk prediction algorithms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective way of stratifying cardiac surgical patients according to operative risk is to use one of several available risk prediction algorithms that incorporate multiple variables to derive a risk score. One of the most widely used algorithms for this purpose in the United States is that developed by the Society of Thoracic Surgeons (STS) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This algorithm, which incorporates patient age, sex, and variables reflecting comorbidities as well as the severity and acuity of cardiac disease, is proprietary and available only to institutions participating in the STS database [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/10\">",
"     10",
"    </a>",
"    ]. Another such algorithm, the EuroSCORE (",
"    <a class=\"graphic graphic_table graphicRef82521 \" href=\"UTD.htm?18/8/18573\">",
"     table 1",
"    </a>",
"    ), is widely used in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], is available, and has been validated in a North American population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One analysis compared the performance of the STS algorithm and the EuroSCORE in predicting the survival of 4497 patients undergoing isolated CABG between 1996 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/14\">",
"     14",
"    </a>",
"    ]. Overall 30 day mortality was 1.9 percent, and was accurately predicted by both risk scores. Within individual deciles of risk, both scores performed well, but the EuroSCORE had significantly greater discriminatory power.",
"   </p>",
"   <p>",
"    A variety of other algorithms are also available for patients undergoing CABG. In a review of 19 such algorithms in 4351 patients undergoing isolated CABG, EuroSCORE had the highest discriminatory power for both 30-day and one year mortality, followed by algorithms from New York State and the Cleveland Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Limitations of the models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle limitation of these risk prediction algorithms is that they may not be applicable to patient populations which differ in one or more significant ways [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/16\">",
"     16",
"    </a>",
"    ]. As the patient population changes, and as surgical technique changes, risk analyses can become outdated. Thus, the greater discriminatory power of the EuroSCORE in the above analysis may derive, at least in part, from the fact that the patient data upon which it is based were collected in 1995, while those upon which the STS algorithm is based were collected from 1990 to 1993. The STS continues to gather new data to permit progressive algorithm revision.",
"   </p>",
"   <p>",
"    Another example of this limitation is that currently most patients referred for CABG undergo an elective procedure, but that the risk models discussed above were derived from patients who underwent both elective and",
"    <span class=\"nowrap\">",
"     urgent/emergent",
"    </span>",
"    procedures. The ACEF (Age, Creatinine, Ejection fraction) score was derived to address this issue as it included only three variables and was developed from a population of individuals who underwent elective open heart surgery at a single institution [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/17\">",
"     17",
"    </a>",
"    ]. ACEF was able to predict mortality as well as or better than five other more complex risk scores such as EUROSCORE or the Cleveland Clinic model.",
"   </p>",
"   <p>",
"    A related limitation is that, as many patients are candidates for either CABG or PCI, a simple, bedside risk prediction model that could be applied to either procedure would be useful. The Mayo Clinic Risk Score (MCRS), which uses seven preprocedural variables, is the first such model. It was initially validated in a population of patients scheduled to undergo PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When tested in over 300,000 patients scheduled to undergo isolated CABG surgery in the Society of Thoracic Surgeons database, there was moderate positive correlation between MCRS and the observed in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/19\">",
"     19",
"    </a>",
"    ]. When compared to the 26 variable STS algorithm, performance was inferior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hospital and surgeon experience",
"    </span>",
"    &nbsp;&mdash;&nbsp;The in-hospital mortality after CABG is related to the volume of CABG procedures performed at the hospital as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of over 900,000 CABG procedures in the Medicare database between 1994 and 1999, the adjusted in-hospital or 30-day mortality was inversely related to hospital volume, ranging from 6.1 percent for hospitals performing &lt;230 procedures per year to 4.8 percent when the volume was &gt;849 procedures per year [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report on over 200,000 procedures from the Society of Thoracic Surgeons (STS) National Cardiac Database between January 2000 and December 2001, the overall operative mortality was 2.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/4\">",
"       4",
"      </a>",
"      ]. The mortality rate ranged from 3.5 percent for hospitals performing &le;150 procedures per year to 2.4 percent for hospitals performing &gt;450 procedures per year.",
"     </li>",
"     <li>",
"      Similar observations have been made in Brazil where a report from the National Health Service for all types of cardiac surgery noted a progressive increase in perioperative mortality from 5.8 percent in hospitals performing more than 341 procedures per year (highest quartile) to 9.7 percent in hospitals performing less than 131 procedures per year (lowest quartile) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association between volume and operative mortality may depend upon patient risk status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the STS database report, adjustment for clinical risk, year of surgery, and patient clustering within centers reduced the impact of annual hospital volume on mortality, with an adjusted mortality range from 3.1 percent (&le;150 procedures) to 2.4 percent (&gt;450 procedures) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/4\">",
"       4",
"      </a>",
"      ]. For patients under 65 years and for those estimated to be at low operative risk, there was no association of hospital volume with mortality.",
"     </li>",
"     <li>",
"      Similar findings were noted in a review of 13,644 patients seen in hospitals performing a low (&lt;200) or high (&gt;200) number of procedures per year: four established predictors (age, gender, surgical priority, and severity of illness) were used to classify risk status (minimal, low, moderate, high, and severe) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/20\">",
"       20",
"      </a>",
"      ]. In-hospital mortality in low volume hospitals was significantly higher in patients at moderate risk (5.3 versus 2.2 percent for high volume hospitals) and high risk (23 versus 12 percent); there was no difference in mortality in the other risk groups.",
"     </li>",
"     <li>",
"      A different conclusion, however, was reached in an analysis of 57,150 CABG operations performed in New York State between 1997 and 1999; there were 1260 (2.2 percent) in-hospital deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/21\">",
"       21",
"      </a>",
"      ]. A logistic regression model was used to classify patient risk as low (predicted in-hospital mortality &lt;2 percent) or moderate to high (predicted in-hospital mortality &ge;2 percent). When low volume hospitals were defined as those performing fewer than 200 operations per year, the odds of in-hospital death were lower at the high volume hospitals for both low and moderate to high risk patients (adjusted odds ratios 0.53 and 0.62, respectively). The advantage of high volume hospitals persisted when the definition of low volume was changed to less than 600 operations per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The experience of the individual surgeon is a predictor of mortality independent of the hospital volume:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of over 200,000 CABG procedures in the Medicare database from 1998 and 1999, operative mortality rates for surgeons performing &lt;101, 101 to 162, and &gt;162 CABGs per year were 5.4, 4.3, and 4.0 percent, respectively (odds ratio 1.36). This relationship remained significant after adjusting for hospital volume (odds ratio 1.33).",
"     </li>",
"     <li>",
"      In the STS database analysis, surgeon volume was also a determinant of risk-adjusted mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/4\">",
"       4",
"      </a>",
"      ]. Surgeons performing 10 to 85, 86 to 138, and &ge;139 CABG procedures annually had overall mortality rates of 2.9, 2.6, and 2.4 percent, respectively. The highest mortality rates (3.3 percent) were observed when patients were treated by low-volume surgeons at low-volume hospitals.",
"     </li>",
"     <li>",
"      In the New York State study, surgeon volume was also a determinant of mortality for both low risk and moderate to high risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/21\">",
"       21",
"      </a>",
"      ]. For low risk patients, either high surgeon volume or high hospital volume or both significantly reduced in-hospital mortality. For moderate to high risk patients, only the combination of both high surgeon volume and high hospital volume was associated with a significant reduction in risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospital volume and the experience of the surgeon also affect the likelihood of early readmission after CABG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H35#H35\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Early readmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of left ventricular dysfunction and heart failure is one of the most important independent predictors of operative mortality and other major adverse events after CABG (",
"    <a class=\"graphic graphic_figure graphicRef77573 \" href=\"UTD.htm?23/37/24159\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a prospective observational study of over 8600 patients undergoing CABG between 1992 and 1997, the operative mortality varied from less than 2 percent with a left ventricular ejection fraction (LVEF) &gt;40 percent to 3.5 to 4 percent with an LVEF between 20 and 40 percent to approximately 8 percent with an LVEF &lt;20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Increasing age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not surprisingly, older age is a predictor of increased risk after CABG (",
"    <a class=\"graphic graphic_figure graphicRef77573 \" href=\"UTD.htm?23/37/24159\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. This is an important issue since an increasing number of elderly patients (&ge;70 years of age) are undergoing CABG.",
"   </p>",
"   <p>",
"    One report retrospectively reviewed the outcome of 3330 patients over the age of 70 in whom isolated CABG was performed between 1982 and 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/25\">",
"     25",
"    </a>",
"    ]. The overall operative mortality decreased from 7.2 to 4.4 percent over the course of the study. The prevalence of high-risk elderly patients rose from 16.2 to 26.9 percent, but the operative mortality in these individuals fell from 17.2 to 8.9 percent. Independent predictors of mortality in older adults were similar to those of younger patients and included poor left ventricular function, previous CABG, female sex, peripheral artery disease, and diabetes.",
"   </p>",
"   <p>",
"    A later report evaluated the outcome of 725 patients &ge;80 years of age who underwent CABG between 1996 and 2001 in Canadian centers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/26\">",
"     26",
"    </a>",
"    ]. By 2001, 6.2 percent of bypass operations were performed in octogenarians. Compared to younger patients, octogenarians have significantly higher rates of in-hospital mortality (9.2 versus 3.8 percent) and stroke (4.7 versus 1.6 percent) after CABG. After adjustment of comorbidities, age &ge;80 was an independent predictor of mortality. The relative increase in mortality was greatest with urgent (10. versus 3.9) and emergency surgery (17.0 versus 6.8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EuroSCORE risk prediction algorithm includes underlying chronic kidney disease (serum creatinine &gt;2.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [200",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    as a risk factor for surgical mortality (",
"    <a class=\"graphic graphic_table graphicRef82521 \" href=\"UTD.htm?18/8/18573\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. A subsequent prospective study of 4403 consecutive patients undergoing first-time isolated CABG found that even mild renal dysfunction (serum creatinine 1.5 to 2.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133 to 199",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    was associated with a higher operative mortality than in patients with serum creatinine concentrations under 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1 versus 2.1 percent, multivariate adjusted odds ratio 1.91, 95% CI 1.18-3.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A graded relationship between the degree of renal dysfunction and operative mortality was noted in a report from the Society of Thoracic Surgeons National Adult Cardiac Database of almost 500,000 patients undergoing isolated CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/28\">",
"     28",
"    </a>",
"    ]. Operative mortality rose from 1.3 percent in patients with a normal estimated glomerular filtration rate (GFR &ge;90",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    to 1.8 percent with a GFR of 60 to 89",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (mild kidney disease, present in 51 percent), 4.3 percent with a GFR of 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (moderate kidney disease, present in 24 percent), and 9.0 to 9.3 percent with a GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or on dialysis (severe kidney disease, present in 4 percent). After multivariable adjustment, preoperative GFR was one of the most powerful predictors of operative mortality (adjusted odds ratio for mortality 1.55 and 3.82 with moderate and severe kidney disease, respectively).",
"   </p>",
"   <p>",
"    In addition to the increase in operative mortality and morbidity, chronic kidney disease is also predictor of increased long-term mortality after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/29\">",
"     29",
"    </a>",
"    ]. This finding is consistent with the long-term increase in cardiovascular risk associated with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H20#H20\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Predictors of mortality'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     New Q waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;New Q waves developing after CABG were associated with increased in-hospital mortality in a report from the Coronary Artery Surgery Study (9.7 versus 1.0 percent in those without new Q waves) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/30\">",
"     30",
"    </a>",
"    ]. Although usually reflecting a new MI, new Q waves after CABG can also represent unmasking of a previous MI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Single or multiple IMA grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of the left internal mammary artery (LIMA) is associated with a higher graft patency rate and a lower perioperative mortality, similar to the known benefit of an arterial graft on long-term outcome compared to SVGs (",
"    <a class=\"graphic graphic_figure graphicRef72584 \" href=\"UTD.htm?23/28/24013\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69211 \" href=\"UTD.htm?20/46/21229\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. One study of 21,873 patients who underwent an isolated, first-time CABG found that the adjusted odds ratio for in-hospital mortality with the use of a LIMA, compared to no LIMA, was 0.40 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/34\">",
"     34",
"    </a>",
"    ]. LIMA grafts were protective across all major patient and disease groups.",
"   </p>",
"   <p>",
"    Because of the better outcomes with arterial compared to saphenous vein grafts, there is increasing use of multiple arterial grafts in patients with multivessel disease. In-hospital mortality appears to be similar with multiple and single arterial grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Coronary artery diameter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative mortality is increased with smaller coronary artery diameters, which may explain the increased risk that has been observed in women, particularly those &lt;50 years of age, and smaller people [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. It is possible that smaller coronary arteries are more likely to be associated with thrombosis, technical difficulties, and reduced short-term graft patency. These issues were evaluated in a prospective study of 1325 patients undergoing CABG: small mid left anterior descending artery (LAD) diameter was associated with an increase in in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.0 mm diameter &mdash; 15.8 percent",
"     </li>",
"     <li>",
"      1.5-2.0 mm diameter &mdash; 4.6 percent",
"     </li>",
"     <li>",
"      2.5-3.5 mm diameter &mdash; 1.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vessel size was strongly correlated with sex and body size measures (body surface area, body mass index, height, and weight). After adjusting for age and body size, sex remained an important predictor of coronary artery size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gastrointestinal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) complications after CABG are infrequent but are associated with increased mortality. The largest reported experience comes from the United States Agency for Healthcare Research and Quality, which assessed the incidence and impact of GI complications after 2.7 million CABG operations performed from 1998 to 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/41\">",
"     41",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of GI complications was 4.1 percent",
"     </li>",
"     <li>",
"      The inpatient mortality was significantly increased in those with GI complications compared to those without (12.0 versus 2.5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H34#H34\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Gastrointestinal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome, which is a risk factor for cardiovascular disease, is common in patients who undergo CABG. In an observational study of 5304 patients who underwent an isolated CABG, the metabolic syndrome (present in 46 percent of patients) was a significant independent predictor of operative mortality (relative risk 3.04, 95% CI 1.73-5.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link&amp;anchor=H10#H10\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Clinical implications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preoperative anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative anemia is an independent risk factor for early mortality after CABG; two large observational studies support this point [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. For example the Multicenter Study of Preoperative Ischemia Epidemiology II (EPI II) evaluated the relationship between the lowest preoperative hemoglobin concentration and adverse postoperative outcomes in over 4800 patients undergoing elective CABG surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/43,45\">",
"     43,45",
"    </a>",
"    ]. Preoperative anemia (&lt;13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in men and &lt;12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women) was present in 28 and 36 percent of patients, respectively. CABG patients with preoperative anemia (starting at hemoglobin concentrations &lt;11",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    were at increased risk of postoperative cardiac and noncardiac events in a dose-dependent manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Duration of red cell storage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longer red blood cell storage times are associated with structural and functional changes that may worsen outcomes in the recipient. In a retrospective study of over 6000 patients who underwent open heart surgery and were transfused, those who received blood stored for more than 14 days had significantly worse outcomes (intubation beyond 72 hours, renal failure, sepsis or septicemia, and in-hospital and one-year mortality) compared to those with shorter storage times [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22120/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other studies have not demonstrated an independent effect of red cell storage time on outcomes after coronary artery bypass graft surgery and any potential benefits of using blood stored for two weeks or less must be weighed against the difficulty of maintaining the blood supply if only fresher units are used for transfusion. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of red blood cells for transfusion\", section on 'Clinical relevance of storage time'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"       \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194219473\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The perioperative mortality for patients undergoing coronary artery bypass graft surgery (CABG) varies according to the extent of patient comorbidities. Mortality is about 1 percent for the lowest risk elective patients and 2 to 5 percent for all patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Operative mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of preoperative and intraoperative factors have been demonstrated to influence the rate of operative mortality after CABG. These include hospital and surgeon experience, degree of left ventricular systolic dysfunction, increasing age, the presence and extent chronic kidney disease, and the type and number of bypass grafts. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Predictors of risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk prediction algorithms have been developed to predict perioperative risk. EuroSCORE and the Society of Thoracic Surgeons (STS) algorithm are two widely used examples. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk prediction algorithms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/1\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/2\">",
"      Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005; 352:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/3\">",
"      Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/4\">",
"      Peterson ED, Coombs LP, DeLong ER, et al. Procedural volume as a marker of quality for CABG surgery. JAMA 2004; 291:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/5\">",
"      Nallamothu BK, Saint S, Hofer TP, et al. Impact of patient risk on the hospital volume-outcome relationship in coronary artery bypass grafting. Arch Intern Med 2005; 165:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/6\">",
"      Cram P, Rosenthal GE, Vaughan-Sarrazin MS. Cardiac revascularization in specialty and general hospitals. N Engl J Med 2005; 352:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/7\">",
"      Ribeiro AL, Gagliardi SP, Nogueira JL, et al. Mortality related to cardiac surgery in Brazil, 2000-2003. J Thorac Cardiovasc Surg 2006; 131:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/8\">",
"      Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg 1994; 57:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/9\">",
"      Hattler BG, Madia C, Johnson C, et al. Risk stratification using the Society of Thoracic Surgeons Program. Ann Thorac Surg 1994; 58:1348.",
"     </a>",
"    </li>",
"    <li>",
"     Society of Thoracic Surgeons website at www.sts.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/11\">",
"      Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/12\">",
"      Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/13\">",
"      Nashef SA, Roques F, Hammill BG, et al. Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. Eur J Cardiothorac Surg 2002; 22:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/14\">",
"      Nilsson J, Algotsson L, H&ouml;glund P, et al. Early mortality in coronary bypass surgery: the EuroSCORE versus The Society of Thoracic Surgeons risk algorithm. Ann Thorac Surg 2004; 77:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/15\">",
"      Nilsson J, Algotsson L, H&ouml;glund P, et al. Comparison of 19 pre-operative risk stratification models in open-heart surgery. Eur Heart J 2006; 27:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/16\">",
"      Kolh P. Importance of risk stratification models in cardiac surgery. Eur Heart J 2006; 27:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/17\">",
"      Ranucci M, Castelvecchio S, Menicanti L, et al. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation 2009; 119:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/18\">",
"      Singh M, Rihal CS, Lennon RJ, et al. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc 2007; 82:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/19\">",
"      Singh M, Gersh BJ, Li S, et al. Mayo Clinic Risk Score for percutaneous coronary intervention predicts in-hospital mortality in patients undergoing coronary artery bypass graft surgery. Circulation 2008; 117:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/20\">",
"      Nallamothu BK, Saint S, Ramsey SD, et al. The role of hospital volume in coronary artery bypass grafting: is more always better? J Am Coll Cardiol 2001; 38:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/21\">",
"      Wu C, Hannan EL, Ryan TJ, et al. Is the impact of hospital and surgeon volumes on the in-hospital mortality rate for coronary artery bypass graft surgery limited to patients at high risk? Circulation 2004; 110:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/22\">",
"      Fortescue EB, Kahn K, Bates DW. Development and validation of a clinical prediction rule for major adverse outcomes in coronary bypass grafting. Am J Cardiol 2001; 88:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/23\">",
"      Yau TM, Fedak PW, Weisel RD, et al. Predictors of operative risk for coronary bypass operations in patients with left ventricular dysfunction. J Thorac Cardiovasc Surg 1999; 118:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/24\">",
"      Daly LE, Lonergan M, Graham I. Predicting operative mortality after coronary artery bypass surgery in males. Q J Med 1993; 86:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/25\">",
"      Ivanov J, Weisel RD, David TE, Naylor CD. Fifteen-year trends in risk severity and operative mortality in elderly patients undergoing coronary artery bypass graft surgery. Circulation 1998; 97:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/26\">",
"      Baskett R, Buth K, Ghali W, et al. Outcomes in octogenarians undergoing coronary artery bypass grafting. CMAJ 2005; 172:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/27\">",
"      Zakeri R, Freemantle N, Barnett V, et al. Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. Circulation 2005; 112:I270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/28\">",
"      Cooper WA, O'Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006; 113:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/29\">",
"      Hillis GS, Croal BL, Buchan KG, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 2006; 113:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/30\">",
"      Chaitman BR, Alderman EL, Sheffield LT, et al. Use of survival analysis to determine the clinical significance of new Q waves after coronary bypass surgery. Circulation 1983; 67:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/31\">",
"      Bassan MM, Oatfield R, Hoffman I, et al. New Q waves after aortocoronary bypass surgery. Unmasking of an old infarction. N Engl J Med 1974; 290:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/32\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/33\">",
"      Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-thoracic-artery grafts--effects on survival over a 15-year period. N Engl J Med 1996; 334:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/34\">",
"      Leavitt BJ, O'Connor GT, Olmstead EM, et al. Use of the internal mammary artery graft and in-hospital mortality and other adverse outcomes associated with coronary artery bypass surgery. Circulation 2001; 103:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/35\">",
"      Lytle BW, Blackstone EH, Loop FD, et al. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 1999; 117:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/36\">",
"      Ioannidis JP, Galanos O, Katritsis D, et al. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. J Am Coll Cardiol 2001; 37:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/37\">",
"      Endo M, Nishida H, Tomizawa Y, Kasanuki H. Benefit of bilateral over single internal mammary artery grafts for multiple coronary artery bypass grafting. Circulation 2001; 104:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/38\">",
"      O'Connor GT, Morton JR, Diehl MJ, et al. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. The Northern New England Cardiovascular Disease Study Group. Circulation 1993; 88:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/39\">",
"      O'Connor NJ, Morton JR, Birkmeyer JD, et al. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 1996; 93:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/40\">",
"      Vaccarino V, Abramson JL, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation 2002; 105:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/41\">",
"      Rodriguez F, Nguyen TC, Galanko JA, Morton J. Gastrointestinal complications after coronary artery bypass grafting: a national study of morbidity and mortality predictors. J Am Coll Surg 2007; 205:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/42\">",
"      Echahidi N, Pibarot P, Despr&eacute;s JP, et al. Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. J Am Coll Cardiol 2007; 50:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/43\">",
"      Kulier A, Levin J, Moser R, et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007; 116:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/44\">",
"      van Straten AH, Hamad MA, van Zundert AJ, et al. Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: a comparison with the matched general population. Circulation 2009; 120:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/45\">",
"      Zindrou D, Taylor KM, Bagger JP. Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet 2002; 359:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22120/abstract/46\">",
"      Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1561 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22120=[""].join("\n");
var outline_f21_38_22120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H194219473\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PREVENTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OPERATIVE MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREDICTORS OF RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk prediction algorithms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Limitations of the models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hospital and surgeon experience",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Increasing age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      New Q waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Single or multiple IMA grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Coronary artery diameter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gastrointestinal complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preoperative anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Duration of red cell storage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H194219473\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1561\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1561|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/37/24159\" title=\"figure 1\">",
"      Predictive model for outcome after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24013\" title=\"figure 2\">",
"      IMA versus vein graft patency after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/46/21229\" title=\"figure 3\">",
"      Survival advantage of arterial coronary bypass grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1561|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/8/18573\" title=\"table 1\">",
"      EuroSCORE risk index",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2168?source=related_link\">",
"      Prevention of neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_38_22121="Differentiating uterine leiomyomas (fibroids) from uterine sarcomas";
var content_f21_38_22121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differentiating uterine leiomyomas (fibroids) from uterine sarcomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22121/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22121/contributors\">",
"     Elizabeth A Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22121/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22121/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22121/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/38/22121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/38/22121/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/38/22121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16656355\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign uterine leiomyomas (fibroids) are the most common pelvic tumor in women (estimated lifetime risk of 70 percent in white women and 80 percent in African American women) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Uterine sarcoma is rare (3 to 7 per 100,000 United States population) with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/4\">",
"     4",
"    </a>",
"    ]. Clinicians who are evaluating a woman with presumed leiomyomas are presented with the clinical challenge of deciding which patients may have sarcoma. The prevalence of sarcoma in women undergoing hysterectomy for a preoperative diagnosis of leiomyomas is 0.2 to 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, hysterectomy was the mainstay of treatment for women with a uterine mass, and uterine sarcoma, if present, was identified by pathologic analysis. In current practice, women with presumed benign leiomyomas are treated with a variety of medical and conservative surgical or interventional procedures. Non-excisional therapies for fibroid-related symptoms (eg, hormonal contraception, endometrial ablation, interventional radiology procedures) do not produce specimens for pathologic examination. Thus, the diagnosis of malignant disease may be missed. An equally important priority, however, is to avoid unnecessary surgery for the purpose of excluding sarcoma.",
"   </p>",
"   <p>",
"    Approaches to differentiating benign uterine leiomyomas from uterine sarcoma are reviewed here. General principles of the diagnosis of uterine leiomyomas, the diagnosis and treatment of uterine sarcoma, and benign and atypical leiomyoma variants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15257?source=see_link\">",
"     \"Treatment and prognosis of uterine leiomyosarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link\">",
"     \"Variants of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./classification-and-treatment-of-endometrial-stromal-tumors?source=see_link\">",
"     \"Classification and treatment of endometrial stromal tumors\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2222936\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF A UTERINE MASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The challenge of differentiating a leiomyoma from a uterine sarcoma is one part of the diagnostic process for all women with a uterine mass. The differential diagnosis of an enlarged uterus includes both benign and malignant conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benign leiomyoma",
"     </li>",
"     <li>",
"      Leiomyoma variant",
"     </li>",
"     <li>",
"      Uterine adenomyoma or diffuse adenomyosis",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Hematometra",
"     </li>",
"     <li>",
"      Uterine sarcoma",
"     </li>",
"     <li>",
"      Uterine carcinosarcoma",
"     </li>",
"     <li>",
"      Endometrial carcinoma",
"     </li>",
"     <li>",
"      Metastatic disease (typically from another reproductive tract primary)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of an enlarged uterus is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H5289858#H5289858\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16656371\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing clinical characteristics is the initial approach to evaluating a patient with a presumed leiomyoma in whom there is some concern of uterine sarcoma. Suspicion of sarcoma may change based upon a patient&rsquo;s risk factors or response to treatment. Unfortunately, the clinical manifestations of benign leiomyomas and uterine sarcomas are indistinguishable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1430439\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1430399\">",
"    <span class=\"h3\">",
"     Risk factors common to both leiomyomas and sarcomas",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2222315\">",
"    <span class=\"h4\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk and incidence of fibroids is two- to three-fold greater in black women than in white women. The cumulative incidence of fibroids of any size, including very small tumors, by age 50 is &gt;80 percent for black women and almost 70 percent for whites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, African-American women have an approximately two-fold higher incidence of leiomyosarcomas (but not other types of uterine sarcoma) and carcinosarcoma than white women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H15672748#H15672748\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Race'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44585?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1430423\">",
"    <span class=\"h3\">",
"     Risk factors for sarcomas only",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16657504\">",
"    <span class=\"h4\">",
"     Increasing age and postmenopausal status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign leiomyomas develop primarily in women of reproductive age, with symptoms developing on average as early as the 20s in African American women and typically in the 30s or 40s in white women. Fibroids typically stabilize or diminish in size following menopause. Postmenopausal estrogen therapy is associated with the growth of myomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent symptoms, but does not appear to induce the development of new fibroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Prevalence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H26#H26\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Women on hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, increasing age is a significant risk factor for uterine sarcomas and the majority of sarcomas occur after menopause. Young age does not exclude the diagnosis of uterine sarcoma, however, since it has been reported in women as young as their mid-20s [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, for postmenopausal women, a new or growing uterine mass warrants further evaluation for uterine sarcoma. The level of suspicion may be lower in women who are on postmenopausal estrogen therapy and have a small increase in the size of a fibroid known to present prior to menopause. In this subgroup, stopping postmenopausal estrogen therapy is also an option to see if regression occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2222466\">",
"    <span class=\"h4\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (five years or more) is associated with an increase in risk of developing uterine sarcoma. The absolute risk remains small (eg, 0.05 per 1000 women in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/10\">",
"     10",
"    </a>",
"    ]. In general, sarcomas present two to five years following the start of tamoxifen therapy and are often at an advanced stage at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There is no known relationship between tamoxifen-associated endometrial polyps and uterine sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H15672769#H15672769\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Tamoxifen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link&amp;anchor=H11#H11\">",
"     \"Endometrial polyps\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673271\">",
"    <span class=\"h4\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other risk factors that are associated with uterine sarcoma, but not with leiomyomas, include pelvic irradiation, a history of childhood retinoblastoma, and Hereditary Leiomyomatosis and Renal Cell Carcinoma syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H15672842#H15672842\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Pelvic radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H15674059#H15674059\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Hereditary conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are inconclusive regarding parity and time of menarche and menopause as risk factors for sarcoma. For benign leiomyomas, early menarche (&lt;10 years old) is a risk factor (particularly in black women) and parity decreases the chances of fibroid formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Prevalence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H15672803#H15672803\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1430474\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding, pelvic",
"    <span class=\"nowrap\">",
"     pain/pressure,",
"    </span>",
"    and a pelvic mass are the primary presenting",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    for both leiomyomas and sarcoma, making it difficult to differentiate between the two on this basis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/9,13-15\">",
"     9,13-15",
"    </a>",
"    ]. Some women with sarcoma have presented with a foul-smelling vaginal discharge, but this is not a reliable indicator of malignancy since vaginal discharge is a common gynecologic symptom. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H14#H14\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical manifestations associated with metastatic disease may be found in women with sarcoma, but not with ordinary leiomyomas. Uterine sarcomas spread via intraabdominal, lymphatic, or hematogenous routes. Hematogenous spread is most often to the lungs. Of note, some benign leiomyoma variants also disseminate and must be excluded if widespread disease is found. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link&amp;anchor=H1167264#H1167264\">",
"     \"Variants of uterine leiomyomas (fibroids)\", section on 'Benign uterine variants with extrauterine disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15257?source=see_link\">",
"     \"Treatment and prognosis of uterine leiomyosarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./classification-and-treatment-of-endometrial-stromal-tumors?source=see_link&amp;anchor=H39278677#H39278677\">",
"     \"Classification and treatment of endometrial stromal tumors\", section on 'Evaluation of suspected disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23337528\">",
"    <span class=\"h2\">",
"     Failure to respond to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to respond to medical treatment or non-excisional procedures (endometrial ablation, uterine artery embolization, and magnetic resonance guided focused ultrasound) for leiomyomas has preceded a diagnosis of malignancy in multiple reports [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. However, such treatment failures are not definitive evidence of malignancy. &nbsp;",
"   </p>",
"   <p>",
"    The concept of response to hormonal treatment has been proposed as a method of differentiating between uterine leiomyoma and sarcoma. The rationale is that a trial of a gonadotropin releasing hormone agonist would cause shrinkage in leiomyomas, but not sarcomas. This approach has not proved useful, however, since the few data regarding this approach are mixed, with one report of shrinkage in a leiomyosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16656415\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of uterine sarcoma is based upon histologic examination. Uterine sarcomas are most commonly diagnosed following myomectomy or hysterectomy for presumed leiomyomas. Preoperative and intraoperative findings are of limited value in estimating the likelihood that a mass is a uterine sarcoma. Magnetic resonance imaging (MRI) and endometrial sampling are the most potentially useful techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23336962\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1430498\">",
"    <span class=\"h3\">",
"     Pelvic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough pelvic examination should be performed in all women with a pelvic mass. The size, contour, and mobility of the uterus should be noted, along with any other findings (eg, adnexal mass, cervical mass). These findings are helpful to follow changes in the uterus over time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to aid surgical planning (eg, plan a transverse or vertical skin incision). Unfortunately, however, there are no examination findings that distinguish a leiomyoma from a uterine sarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23338477\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small case series have reported elevated levels of serum level of CA 125 and subtypes of lactate dehydrogenase in women with uterine sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. However, use of these markers for this indication is investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1430514\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21562275\">",
"    <span class=\"h4\">",
"     Choice of imaging modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no pelvic imaging modality that can reliably differentiate between benign leiomyomas and uterine sarcomas. Leiomyomas and uterine sarcomas appear similar, both are focal masses within the uterus and both often have central necrosis.",
"   </p>",
"   <p>",
"    MRI may be helpful in women in whom there is a suspicion of sarcoma; however, it does not provide a definitive diagnosis. High signal intensity is not a reliable indicator of uterine sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/26\">",
"     26",
"    </a>",
"    ]. A consistent finding in leiomyosarcomas is the absence of calcifications. Some data suggest that ill-defined margins are consistent with a sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/27\">",
"     27",
"    </a>",
"    ]. Two small studies using different techniques of MRI with gadolinium contrast have reported specificities of 93 to 100 percent and positive predictive values of 53 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/23,28\">",
"     23,28",
"    </a>",
"    ]. Further study of use of MRI for this purpose is needed.",
"   </p>",
"   <p>",
"    Sonographic evaluation of a uterine mass may identify features suggestive of sarcoma (mixed echogenic and poor echogenic parts, central necrosis, and color Doppler findings of irregular vessel distribution, low impedance to flow, and high peak systolic velocity); however, many of these characteristics may also be found in benign leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography does not reliably differentiate between leiomyomas and uterine sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography with fluorodeoxyglucose (FDG) does not appear to be useful to distinguish between leiomyomas and uterine sarcomas. While the FDG uptake is generally high in sarcomas and low in leiomyomas, the uptake varies across individual tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the limitations of pelvic imaging, however, we suggest that women with a pelvic mass that is newly diagnosed or has changed markedly in size or mobility undergo a pelvic ultrasound as an initial imaging study to exclude other etiologies of uterine enlargement. If uterine sarcoma is suspected based upon clinical characteristics of the patient or mass or upon sonographic findings, MRI with gadolinium contrast may aid in assessing the likelihood of malignancy.",
"   </p>",
"   <p>",
"    In addition, in the rare cases in which a woman presents with a uterine mass and symptoms of lung disease (eg, dyspnea), thoracic imaging should be performed to exclude lung metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21562097\">",
"    <span class=\"h4\">",
"     Findings that do NOT reliably predict sarcoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21562104\">",
"    <span class=\"h5\">",
"     Rapidly growing uterine mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;In reproductive age women, the common teaching has been that rapid growth of a uterine mass (eg, increasing by six weeks&rsquo; gestational size within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/5\">",
"     5",
"    </a>",
"    ]) is a sign of a potential uterine sarcoma. This concept appears to date back to the era when pelvic examinations alone were used to assess uterine size [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/31\">",
"     31",
"    </a>",
"    ]. With modern pelvic imaging, there is an increased appreciation that, in women of reproductive age, leiomyomas both grow and shrink, and do so at differing rates within the same woman [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. As an example, in a prospective study, 101 fibroids in 36 women were evaluated with MRI at three-month intervals for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/32\">",
"     32",
"    </a>",
"    ]. Increase in volume of &ge;30 percent in a three-month period was found in 37 myomas; rapid growth was more likely in tumors that were &le;5 cm in diameter.",
"   </p>",
"   <p>",
"    Rapid growth may occur in either a sarcoma or a benign leiomyoma. In addition, it is theoretically possible for a sarcoma to remain indolent for a long period of time and only come to diagnostic attention when a more aggressive phase of disease is entered.",
"   </p>",
"   <p>",
"    The teaching about rapid growth of a uterine mass being associated with an increased risk of uterine sarcoma was",
"    <strong>",
"     not",
"    </strong>",
"    substantiated in a study of 1332 women who underwent hysterectomy or myomectomy of presumed uterine leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of uterine sarcoma was low for all women, with a similar incidence in the 371 women with a rapidly growing uterus by clinical or ultrasound examination (1 uterine sarcoma; 0.27 percent) and in the 961 without rapid uterine growth (2 uterine sarcomas; 0.15 percent). In addition, a literature review of 26 studies found that a history of rapid uterine enlargement was documented in only 15 of 580 patients (2.6 percent) with uterine sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, the great majority of women with a rapidly enlarging uterus or uterine mass do not have a sarcoma.",
"   </p>",
"   <p>",
"    In contrast, postmenopausal women who have a uterine mass that is new or is growing at either a slow or rapid pace should be evaluated for malignancy. The level of suspicion for uterine sarcoma is lower in women who are on postmenopausal estrogen therapy and have a small increase in the size of a presumed fibroid known to have been present prior to menopause. (See",
"    <a class=\"local\" href=\"#H16657504\">",
"     'Increasing age and postmenopausal status'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21562111\">",
"    <span class=\"h5\">",
"     Large or solitary uterine mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies have reported that a sarcoma is often the largest (or the only) mass within a uterus, averaging 7 to 9 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/9,13,36\">",
"     9,13,36",
"    </a>",
"    ]. However, leiomyomas may also be singular and may be of any size. Although data are limited, large uterine size (in excess of 20 gestational weeks) has also not been shown to be associated with sarcoma risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/9,37\">",
"     9,37",
"    </a>",
"    ]. As a result, these features are not useful in identifying malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1430522\">",
"    <span class=\"h3\">",
"     Biopsy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289628\">",
"    <span class=\"h4\">",
"     Endometrial sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial sampling yields a diagnosis of uterine sarcoma in some, but not all, patients (reports range from 38 to 64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/7,38,39\">",
"     7,38,39",
"    </a>",
"    ]. Since this is a minimally invasive procedure and is already indicated in many women with abnormal uterine bleeding to exclude endometrial neoplasia, we suggest sampling in women in whom sarcoma is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H15#H15\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289635\">",
"    <span class=\"h4\">",
"     Needle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of minimally invasive needle biopsy of a uterine mass (guided by pelvic imaging or laparoscopy) has been proposed, but is currently investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/40\">",
"     40",
"    </a>",
"    ]. Limitations of this method are that the accurate diagnosis of sarcoma requires sampling of multiple sites. (See",
"    <a class=\"local\" href=\"#H23338543\">",
"     'Postoperative pathologic analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23336991\">",
"    <span class=\"h2\">",
"     Intraoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During myomectomy, some tumor characteristics may raise suspicion of malignancy. Frozen section analysis cannot definitively diagnose or exclude uterine sarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23337003\">",
"    <span class=\"h3\">",
"     Gross characteristics of the mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;During excisional surgery, uterine sarcomas may appear or feel different than leiomyomas. Potential features of sarcomas compared with leiomyomas include (",
"    <a class=\"graphic graphic_picture graphicRef62254 \" href=\"UTD.htm?29/37/30293\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of the typical whorl pattern",
"     </li>",
"     <li>",
"      Homogeneous texture",
"     </li>",
"     <li>",
"      Yellow color",
"     </li>",
"     <li>",
"      Soft consistency",
"     </li>",
"     <li>",
"      Absence of a bulging surface when the capsule is incised",
"     </li>",
"     <li>",
"      Ill-defined margins &ndash; The mass may be difficult to excise, although this may also be true of an adenomyoma or certain leiomyomas (eg, due to degenerative change or prior treatment with a gonadotropin releasing hormone agonist or antagonist).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detection of such characteristics may raise the suspicion of a sarcoma, but should not be the sole reason for proceeding with an unplanned hysterectomy. These differences are subtle, and their identification relies upon adequate surgical experience with ordinary leiomyomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23363039\">",
"    <span class=\"h3\">",
"     Intraoperative frozen section",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frozen section analysis is not reliable for excluding uterine sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. Multiple areas must be sampled to obtain an accurate diagnosis, while frozen section analysis typically depends upon a limited tissue sample. Thus, there is a high likelihood of a false negative result even if a sarcoma is present. Only a definitive diagnosis of sarcoma on frozen section should influence surgical decisions (eg, whether to perform hysterectomy or staging). (See",
"    <a class=\"local\" href=\"#H3405629\">",
"     'Should unplanned hysterectomy be performed based on intraoperative findings?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23338543\">",
"    <span class=\"h2\">",
"     Postoperative pathologic analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three criteria are important to the diagnosis of uterine sarcomas: mitotic index, cellular atypia, and geographic areas of coagulative necrosis separated from viable tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The more features exhibited by the lesion, the more likely it is to have clinically aggressive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. There are a number of pathologic entities in which lesions display some, but not all, of the facets of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link&amp;anchor=H23338835#H23338835\">",
"     \"Variants of uterine leiomyomas (fibroids)\", section on 'Smooth muscle tumors of uncertain malignant potential'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis requires examination of multiple sites in the mass [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/42\">",
"     42",
"    </a>",
"    ]. Features of the gross appearance of the tissue, including the color, consistency, and variegation of the incised surface, can help guide sampling of tissue for microscopic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23337504\">",
"    <span class=\"h1\">",
"     CLINICAL CHALLENGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23337512\">",
"    <span class=\"h2\">",
"     Should hysterectomy be performed to exclude uterine sarcoma?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, preoperative and intraoperative findings are of limited value in diagnosing a uterine sarcoma. The best clinical estimate of the likelihood of uterine sarcoma depends upon a constellation of factors. These include the patient&rsquo;s risk factors, response to prior therapy, and the findings of MRI and endometrial sampling. In the rare cases in which a woman presents with a uterine mass and symptoms of lung lesions (eg, dyspnea), evidence of lung metastases on thoracic imaging greatly increases the likelihood of a malignant process. However, benign metastasizing leiomyomas is a benign condition that may also present with lung lesions (eg, (see",
"    <a class=\"local\" href=\"#H1430439\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23337528\">",
"     'Failure to respond to treatment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21562275\">",
"     'Choice of imaging modality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H289628\">",
"     'Endometrial sampling'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link&amp;anchor=H9293634#H9293634\">",
"     \"Variants of uterine leiomyomas (fibroids)\", section on 'Benign metastasizing leiomyomas'",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    For women in whom uterine sarcoma is suspected, counseling regarding whether to proceed with hysterectomy should include the best clinical estimate of the likelihood of sarcoma and the potential morbidity of hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=see_link&amp;anchor=H1745544#H1745544\">",
"     \"Abdominal hysterectomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21561641\">",
"    <span class=\"h3\">",
"     Asymptomatic women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy should not be performed in most women with asymptomatic presumed leiomyomas for the sole purpose of excluding a uterine sarcoma. The most important factor in such decisions is the rarity of uterine sarcoma. The likelihood of finding sarcoma in women with a preoperative diagnosis of leiomyomas has been consistently reported in observational studies of 900 or more women as 0.2 to 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. This risk is much lower than the risk of severe complications associated with hysterectomy (3.5 to 11.0 percent) for benign disease found in studies of 1000 to 30,000 hysterectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This recommendation is in agreement with the American College of Obstetricians and Gynecologist (ACOG), which advises that there is insufficient evidence to support hysterectomy for asymptomatic leiomyomas solely to rule out malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, the risk of a missed diagnosis of sarcoma in a small number of women does not appear to outweigh exposing other women to the risks of unnecessary hysterectomy. In our practice, the primary exceptions we make to this are for women in whom endometrial sampling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI strongly suggest sarcoma or those with thoracic imaging consistent with lung metastases. Hysterectomy is also a reasonable option for women with multiple risk factors for uterine sarcoma. (See",
"    <a class=\"local\" href=\"#H1430439\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21562275\">",
"     'Choice of imaging modality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H289628\">",
"     'Endometrial sampling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Following the detection of presumed uterine fibroids in an asymptomatic woman, there are no high quality data to guide follow-up. We order an initial imaging study (usually an ultrasound) to confirm that a pelvic mass is consistent with a fibroid rather than with other etiologies (eg, ovarian mass). After this initial evaluation, we perform annual pelvic examinations. If the characteristics of the uterus change or symptoms develop, we proceed with further evaluation and patient counseling regarding treatment options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\", section on 'Expectant management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21561648\">",
"    <span class=\"h3\">",
"     Symptomatic women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with symptomatic leiomyomas, hysterectomy is one of several treatment options. The advantage of hysterectomy is that it is a definitive procedure, but the disadvantages are loss of fertility, risk of surgical complications, and the time needed for recovery. In some women, the question may arise of whether to choose hysterectomy, in order to exclude malignancy, rather than a conservative treatment.",
"   </p>",
"   <p>",
"    As with women with asymptomatic presumed leiomyomas, for most women with a symptomatic uterine mass, we recommend not choosing hysterectomy rather than other treatments based solely upon the goal of excluding malignancy. Reasonable exceptions to this are women with endometrial sampling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI results that strongly suggest sarcoma, thoracic imaging consistent with lung metastases, or multiple risk factors for uterine sarcoma.",
"   </p>",
"   <p>",
"    On the other hand, for women deciding between several options for treatment of symptomatic fibroids, excluding malignancy may be a potential benefit of hysterectomy. In addition, women who fail to respond to conservative therapy may have an increased risk of sarcoma and also may require definitive treatment. Thus, excluding malignancy may be one factor that influences the decision regarding whether to choose treatment with hysterectomy. (See",
"    <a class=\"local\" href=\"#H1430439\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23337528\">",
"     'Failure to respond to treatment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21562275\">",
"     'Choice of imaging modality'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H289628\">",
"     'Endometrial sampling'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3405629\">",
"    <span class=\"h2\">",
"     Should unplanned hysterectomy be performed based on intraoperative findings?",
"    </span>",
"    &nbsp;&mdash;&nbsp;During myomectomy or other pelvic surgery, a surgeon may encounter findings suggestive of a uterine sarcoma. Intraoperative findings rarely indicate the need for an unplanned hysterectomy and sending pathology samples for evaluation and planning a potential second surgery pending the results is usually prudent. Gross characteristics of a tumor may be suggestive of sarcoma, but are not diagnostic. Frozen section analysis is often inconclusive. (See",
"    <a class=\"local\" href=\"#H23337003\">",
"     'Gross characteristics of the mass'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The only indications for hysterectomy are a frozen section diagnosis of sarcoma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gross evidence of metastatic disease. One note of caution is that women with apparent intraabdominal metastases may have a primary malignancy at another site or leiomyomatosis peritonealis disseminata, which is a rare and benign condition. Unplanned hysterectomy should not be performed in women of reproductive age without a pathologic diagnosis of sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link&amp;anchor=H16699283#H16699283\">",
"     \"Variants of uterine leiomyomas (fibroids)\", section on 'Leiomyomatosis peritonealis disseminata'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Staging for an incidentally discovered intraabdominal malignancy is best performed by a surgeon experienced in these procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=see_link&amp;anchor=H33#H33\">",
"     \"Abdominal hysterectomy\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18469113\">",
"    <span class=\"h2\">",
"     Do myomectomy or morcellation worsen sarcoma prognosis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques such as myomectomy and morcellation permit less invasive surgical options than abdominal hysterectomy. There are few data regarding the effect of myomectomy or morcellation on sarcoma prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/6,48\">",
"     6,48",
"    </a>",
"    ]. The only comparative study included 110 women with uterine sarcoma who did versus did not have uterine morcellation at the time of hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/49\">",
"     49",
"    </a>",
"    ]. There was no significant difference between the groups in the three-month pelvic recurrence rate (9 versus 4 percent). However, the study was limited by the small number of events and lack of long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the rarity of uterine sarcoma, there does not appear to be a basis for avoiding the use of myomectomy and morcellation in procedures for women with presumed leiomyomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23337327\">",
"    <span class=\"h2\">",
"     Do leiomyomas progress to sarcoma?",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, it appears that uterine sarcomas do not arise from benign leiomyomas, with rare exceptions. Genetic evidence has been inconsistent over the years regarding whether sarcomas arise de novo or whether there is karyotypic evolution from leiomyomas to sarcomas, so called sarcomatous degeneration. The consensus from genetic studies has been that most sarcomas arise independently [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/50\">",
"     50",
"    </a>",
"    ]. Sarcomas typically have complex karyotypes and aneuploidy, while leiomyomas have characteristic rearrangements, many of which are shared by other benign tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/51\">",
"     51",
"    </a>",
"    ]. Intermediate forms between these two patterns had not been described.",
"   </p>",
"   <p>",
"    Histologic studies have found rare examples that appear consistent with progression from a leiomyoma to sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/52\">",
"     52",
"    </a>",
"    ]. The most compelling evidence comes from a rare subgroup of leiomyomas with cellular or atypical histology, based upon data from two clinical and one molecular genetic study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In a clinical study, 3 of 18 women with cellular or atypical variants died of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/38/22121/abstract/53\">",
"     53",
"    </a>",
"    ]. There was a longer latency between diagnosis and death in these patients compared with those with leiomyosarcoma (&gt;6 years versus median of 2.1 years). There are no data regarding how often cellular or atypical histology are associated with such abnormal clinical behavior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link&amp;anchor=H1167790#H1167790\">",
"     \"Variants of uterine leiomyomas (fibroids)\", section on 'Benign histologic variants of leiomyomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15672492\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign uterine leiomyomas (fibroids) are the most common pelvic tumor in women (lifetime risk of 70 to 80 percent). Uterine sarcoma is rare (3 to 7 per 100,000 United States population). The likelihood of finding sarcoma in women with a preoperative diagnosis of leiomyomas is 0.2 to 0.5 percent. (See",
"      <a class=\"local\" href=\"#H16656355\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors that are more closely associated with uterine sarcomas than with leiomyomas include: increasing age, postmenopausal status, long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use, and pelvic radiation. (See",
"      <a class=\"local\" href=\"#H1430439\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations are not useful in distinguishing between leiomyomas and uterine sarcomas, since both typically present with abnormal uterine bleeding, pelvic",
"      <span class=\"nowrap\">",
"       pain/pressure,",
"      </span>",
"      and a pelvic mass. (See",
"      <a class=\"local\" href=\"#H1430474\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A rapidly enlarging uterine mass is",
"      <strong>",
"       not",
"      </strong>",
"      a reliable sign of a uterine sarcoma in women of reproductive age. After menopause, on the other hand, a new or growing uterine mass warrants further evaluation. Postmenopausal hormone therapy may cause an increase in the size of an existing leiomyoma. (See",
"      <a class=\"local\" href=\"#H16657504\">",
"       'Increasing age and postmenopausal status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no pelvic imaging modality that can reliably differentiate between benign leiomyomas and uterine sarcomas. We suggest that women with a pelvic mass that is newly diagnosed or has changed markedly in size or mobility undergo a pelvic ultrasound as an initial imaging study rather than no imaging or imaging with another modality. (See",
"      <a class=\"local\" href=\"#H1430514\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) may be helpful in women in whom there is a suspicion of sarcoma; however, it does not provide a definitive diagnosis. For women in whom uterine sarcoma is suspected based upon characteristics of the patient or mass or upon ultrasound findings, we suggest follow-up imaging with MRI rather than imaging with ultrasound alone or with other modalities. (See",
"      <a class=\"local\" href=\"#H1430514\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial sampling appears to yield a diagnosis of uterine sarcoma in some patients (reports range from 38 to 64 percent). We suggest endometrial sampling for women in whom uterine sarcoma is suspected. (See",
"      <a class=\"local\" href=\"#H289628\">",
"       'Endometrial sampling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women with presumed uterine leiomyomas, whether asymptomatic or symptomatic, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      performing hysterectomy for the sole purpose of excluding malignancy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Reasonable exceptions to this are women with endometrial sampling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MRI results that strongly suggest sarcoma, those with thoracic imaging consistent with lung metastases, or those with multiple risk factors for uterine sarcoma. (See",
"      <a class=\"local\" href=\"#H21561641\">",
"       'Asymptomatic women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21561648\">",
"       'Symptomatic women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hysterectomy is among the treatment options for women with women with symptomatic uterine leiomyomas. Women who are considering hysterectomy may view excluding malignancy as a benefit of choosing treatment with hysterectomy. (See",
"      <a class=\"local\" href=\"#H21561648\">",
"       'Symptomatic women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leiomyomas do not appear to progress to sarcoma, with the exception of rare atypical or cellular variants. (See",
"      <a class=\"local\" href=\"#H23337327\">",
"       'Do leiomyomas progress to sarcoma?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/1\">",
"      Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/2\">",
"      Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/3\">",
"      Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/4\">",
"      Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004; 93:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/5\">",
"      Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/6\">",
"      Leung F, Terzibachian JJ, Gay C, et al. [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?]. Gynecol Obstet Fertil 2009; 37:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/7\">",
"      Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990; 162:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/8\">",
"      Takamizawa S, Minakami H, Usui R, et al. Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. Gynecol Obstet Invest 1999; 48:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/9\">",
"      Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/10\">",
"      Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/11\">",
"      Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002; 346:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/12\">",
"      Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/13\">",
"      Schwartz LB, Diamond MP, Schwartz PE. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 1993; 168:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/14\">",
"      Dinh TA, Oliva EA, Fuller AF Jr, et al. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004; 92:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/15\">",
"      Tsikouras P, Liberis V, Galazios G, et al. Uterine sarcoma: a report of 57 cases over a 16-year period analysis. Eur J Gynaecol Oncol 2008; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/16\">",
"      Meyer WR, Mayer AR, Diamond MP, et al. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990; 75:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/17\">",
"      Joyce A, Hessami S, Heller D. Leiomyosarcoma after uterine artery embolization. A case report. J Reprod Med 2001; 46:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/18\">",
"      Common AA, Mocarski EJ, Kolin A, et al. Therapeutic failure of uterine fibroid embolization caused by underlying leiomyosarcoma. J Vasc Interv Radiol 2001; 12:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/19\">",
"      D'Angelo A, Amso NN, Wood A. Uterine leiomyosarcoma discovered after uterine artery embolisation. J Obstet Gynaecol 2003; 23:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/20\">",
"      Loong EP, Wong FW. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid. Fertil Steril 1990; 54:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/21\">",
"      Papadia A, Salom EM, Fulcheri E, Ragni N. Uterine sarcoma occurring in a premenopausal patient after uterine artery embolization: a case report and review of the literature. Gynecol Oncol 2007; 104:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/22\">",
"      Milman D, Zalel Y, Biran H, et al. Unsuspected uterine leiomyosarcoma discovered during treatment with a gonadotropin-releasing hormone analogue: a case report and literature review. Eur J Obstet Gynecol Reprod Biol 1998; 76:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/23\">",
"      Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 2002; 12:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/24\">",
"      Huang GS, Chiu LG, Gebb JS, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007; 107:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/25\">",
"      Hoskins PJ, Le N. Preoperative tumor markers at diagnosis in women with malignant mixed m&uuml;llerian tumors/carcinosarcoma of the uterus. Int J Gynecol Cancer 2008; 18:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/26\">",
"      Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/27\">",
"      Schwartz LB, Zawin M, Carcangiu ML, et al. Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril 1998; 70:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/28\">",
"      Tanaka YO, Nishida M, Tsunoda H, et al. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging 2004; 20:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/29\">",
"      Rha SE, Byun JY, Jung SE, et al. CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol 2003; 181:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/30\">",
"      Kitajima K, Murakami K, Kaji Y, Sugimura K. Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol 2010; 195:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/31\">",
"      MONTAGUE AC, SWARTZ DP, WOODRUFF JD. SARCOMA ARISING IN A LEIOMYOMA OF THE UTERUS: FACTORS INFLUENCING PROGNOSIS. Am J Obstet Gynecol 1965; 92:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/32\">",
"      Baird DD, Garrett TA, Laughlin SK, et al. Short-term change in growth of uterine leiomyoma: tumor growth spurts. Fertil Steril 2011; 95:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/33\">",
"      DeWaay DJ, Syrop CH, Nygaard IE, et al. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002; 100:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/34\">",
"      Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A 2008; 105:19887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/35\">",
"      Kawamura N, Ito F, Ichimura T, et al. Transient rapid growth of uterine leiomyoma in a postmenopausal woman. Oncol Rep 1999; 6:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/36\">",
"      Jones MW, Norris HJ. Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol 1995; 14:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/37\">",
"      West S, Ruiz R, Parker WH. Abdominal myomectomy in women with very large uterine size. Fertil Steril 2006; 85:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/38\">",
"      Bansal N, Herzog TJ, Burke W, et al. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 2008; 110:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/39\">",
"      Sagae S, Yamashita K, Ishioka S, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004; 67:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/40\">",
"      Kawamura N, Ichimura T, Ito F, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer 2002; 94:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/41\">",
"      Schwartz PE, Kelly MG. Malignant transformation of myomas: myth or reality? Obstet Gynecol Clin North Am 2006; 33:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/42\">",
"      Quade BJ. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions. Curr Opin Obstet Gynecol 1995; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/43\">",
"      Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/44\">",
"      Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/45\">",
"      Maresh MJ, Metcalfe MA, McPherson K, et al. The VALUE national hysterectomy study: description of the patients and their surgery. BJOG 2002; 109:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/46\">",
"      Garry R, Fountain J, Mason S, et al. The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy. BMJ 2004; 328:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/47\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 2008; 112:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/48\">",
"      Rekha W, Amita M, Sudeep G, Hemant T. Unexpected complication of uterine myoma morcellation. Aust N Z J Obstet Gynaecol 2005; 45:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/49\">",
"      Morice P, Rodriguez A, Rey A, et al. Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol 2003; 24:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/50\">",
"      Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet 2007; 16 Spec No 1:R7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/51\">",
"      Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/52\">",
"      Robboy SJ, Bentley RC, Butnor K, Anderson MC. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 2000; 108 Suppl 5:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/53\">",
"      Giuntoli RL 2nd, Gostout BS, DiMarco CS, et al. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med 2007; 52:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/54\">",
"      Christacos NC, Quade BJ, Dal Cin P, Morton CC. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 2006; 45:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/38/22121/abstract/55\">",
"      Taran FA, Weaver AL, Gostout BS, Stewart EA. Understanding cellular leiomyomas: a case-control study. Am J Obstet Gynecol 2010; 203:109.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14203 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22121=[""].join("\n");
var outline_f21_38_22121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15672492\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16656355\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2222936\">",
"      DIFFERENTIAL DIAGNOSIS OF A UTERINE MASS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16656371\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1430439\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1430399\">",
"      - Risk factors common to both leiomyomas and sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2222315\">",
"      Race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1430423\">",
"      - Risk factors for sarcomas only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16657504\">",
"      Increasing age and postmenopausal status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2222466\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15673271\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1430474\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23337528\">",
"      Failure to respond to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16656415\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23336962\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1430498\">",
"      - Pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23338477\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1430514\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21562275\">",
"      Choice of imaging modality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21562097\">",
"      Findings that do NOT reliably predict sarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21562104\">",
"      - Rapidly growing uterine mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21562111\">",
"      - Large or solitary uterine mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1430522\">",
"      - Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H289628\">",
"      Endometrial sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H289635\">",
"      Needle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23336991\">",
"      Intraoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23337003\">",
"      - Gross characteristics of the mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23363039\">",
"      - Intraoperative frozen section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23338543\">",
"      Postoperative pathologic analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23337504\">",
"      CLINICAL CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23337512\">",
"      Should hysterectomy be performed to exclude uterine sarcoma?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21561641\">",
"      - Asymptomatic women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21561648\">",
"      - Symptomatic women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3405629\">",
"      Should unplanned hysterectomy be performed based on intraoperative findings?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18469113\">",
"      Do myomectomy or morcellation worsen sarcoma prognosis?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23337327\">",
"      Do leiomyomas progress to sarcoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15672492\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14203|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/37/30293\" title=\"picture 1\">",
"      Leiomyosarcoma gross appearance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classification-and-treatment-of-endometrial-stromal-tumors?source=related_link\">",
"      Classification and treatment of endometrial stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44585?source=related_link\">",
"      Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15257?source=related_link\">",
"      Treatment and prognosis of uterine leiomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=related_link\">",
"      Variants of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_38_22122="Small plaque parapsoriasis";
var content_f21_38_22122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87291%7EDERM%2F87292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87291%7EDERM%2F87292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Small plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small erythematous patches with fine scaling are characteristic of small plaque parapsoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Small plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small, slightly erythematous or brown/yellowish patches and thin plaques with little scaling in a patient with small plaque parapsoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22122=[""].join("\n");
var outline_f21_38_22122=null;
var title_f21_38_22123="US findings active celiac disease";
var content_f21_38_22123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Analysis and ultrasound findings of patients with celiac disease (active versus remission)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Active celiac disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Celiac disease in remission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number (female/male)",
"       </td>",
"       <td>",
"        16 (12/4)",
"       </td>",
"       <td>",
"        34 (27/7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age [years]",
"       </td>",
"       <td>",
"        54 &plusmn; 15 [27 - 77]",
"       </td>",
"       <td>",
"        42 &plusmn; 14 [18 - 72]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Laundry phenomenon\"",
"       </td>",
"       <td>",
"        16/16 (100 percent)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel wall thickening*",
"       </td>",
"       <td>",
"        4/16 (25 percent)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymph node detection rate &gt;2",
"       </td>",
"       <td>",
"        11/16 (69 percent)",
"       </td>",
"       <td>",
"        1/34 (3 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spleen volume [mL]",
"       </td>",
"       <td>",
"        118 &plusmn; 34 [56 - 192]",
"       </td>",
"       <td>",
"        91 &plusmn; 26 [33 - 129]",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All patients with circumscribed (malignant) bowel wall thickening revealed a \"laundry phenomenon\" (hyperechoic images, like laundry in the drum of a washing machine)&nbsp;and showed enlarged mesenteric lymph nodes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22123=[""].join("\n");
var outline_f21_38_22123=null;
var title_f21_38_22124="Compare IHC markers melanoma";
var content_f21_38_22124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of five immunohistochemical markers in melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        S-100",
"       </td>",
"       <td class=\"subtitle1\">",
"        MART-1/Melan-A",
"       </td>",
"       <td class=\"subtitle1\">",
"        HMB-45",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mitf",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tyrosinase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Antigen makeup",
"        </strong>",
"       </td>",
"       <td>",
"        Calcium-binding protein",
"       </td>",
"       <td>",
"        Melanocyte differentiation antigen expressed as a transmembrane protein",
"       </td>",
"       <td>",
"        Part of gp 100 complex (pre-melanosome complex)",
"       </td>",
"       <td>",
"        Transcription regulator of tyrosinase gene",
"       </td>",
"       <td>",
"        Key enzyme in melanin biosynthesis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Staining targets",
"        </strong>",
"       </td>",
"       <td>",
"        Melanoma, benign nevic cells, (activated junctional nevi, dermal nevic cells in patients with HIV, blue nevi, and deep penetrating nevi), schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors, among others",
"       </td>",
"       <td>",
"        Cells of melanocytic lineage, modified perivascular smooth muscle cells of lymphangiomyomatosis, clear cell sugar tumor of the lung, renal angiomyolipoma, adrenocortical tumors, and tumors of the ovary",
"       </td>",
"       <td>",
"        Most melanomas, fetal and neonatal melanocytes, intraepidermal and superficial dermal components of benign nevi, blue nevi, and deep-penetrating nevi",
"       </td>",
"       <td>",
"        Melanoma, benign, melanocytes, some perivascular epithelioid cell carcinoma, and clear cell carcinoma",
"       </td>",
"       <td>",
"        Melanoma, normal melanocytes, and nevi",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Staining location",
"        </strong>",
"       </td>",
"       <td>",
"        Nucleus",
"       </td>",
"       <td>",
"        Cytoplasm",
"       </td>",
"       <td>",
"        Cytoplasm",
"       </td>",
"       <td>",
"        Nucleus",
"       </td>",
"       <td>",
"        Cytoplasm",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Comments",
"        </strong>",
"       </td>",
"       <td>",
"        Very high sensitivity but low specificity",
"       </td>",
"       <td>",
"        Sensitive and specific for melanocytes, but is not a marker of malignant transformation",
"       </td>",
"       <td>",
"        Does not react with spindle-cell melanomas",
"       </td>",
"       <td>",
"        May be more sensitive and specific than currently commercially available markers. A promising marker.",
"       </td>",
"       <td>",
"        May have higher sensitivity for metastatic tumors than HMB-45 or MART-1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Mitf: microphthalmia transcription factor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22124=[""].join("\n");
var outline_f21_38_22124=null;
var title_f21_38_22125="Potential candidates for fertility preservation interventions";
var content_f21_38_22125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diseases in which affected individuals may benefit from fertility preservation interventions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignant diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Childhood cancers*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hodgkin's and non-Hodgkin's lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ewing's sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pelvic osteosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wilm's tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genital rhabdomyosarcoma",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Burkitt lymphoma",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukemia",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroblastoma",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Adult cancers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Breast cancer",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Infiltrative ductal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Stage I-III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Infiltrative lobular",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Stage IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Cancer of the cervix",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Adeno-/adenosquamous carcinoma",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignancies of the gastrointestinal tract",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune and hematological diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behcet's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steroid resistant glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive systemic sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile idiopathic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aplastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Benign ovarian disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign ovarian masses requiring radical surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients receiving pelvic radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Solid organ tumors presenting in the pelvis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ewing's sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osteosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tumors of the spinal cord",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Retroperitoneal sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectal cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic bone disease requiring radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prophylactic oophorectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRCA I and II germline mutation carriers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hematopoietic stem cell transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic, hematological and autoimmune disorders",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Cryopreservation of the ovarian tissue is the only option in children.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      If ovarian tissue is cryopreserved, ovarian metastases should be ruled because of the moderate or high risk of ovarian involvement.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Sonmezer M, Shamonki MI, Oktay K. Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res 2005; 322:125. Copyright &copy; 2005 Springer Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22125=[""].join("\n");
var outline_f21_38_22125=null;
var title_f21_38_22126="Baby lung in ARDS";
var content_f21_38_22126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Baby lung and ARDS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 359px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lung in ARDS has been compared to a \"baby lung\", because only a small functional portion of the organ (surrounded by green) is capable of participating in gas exchange. This region receives a disproportionate amount of the delivered breath. Tidal volumes should be minimized to prevent overdistention of the small portion of functional lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22126=[""].join("\n");
var outline_f21_38_22126=null;
var title_f21_38_22127="Source androgen excess";
var content_f21_38_22127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Determining source of androgen excess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dexamethasone androgen-suppression test (DAST) often permits a positive diagnosis of the characteristic ovarian and adrenal dysfunction of polycystic ovary syndrome (PCOS) and will elucidate rare disorders that mimic PCOS.",
"    <div class=\"footnotes\">",
"     ACTH: adrenocorticotropic hormone; PCOS: polycystic ovary syndrome; SD: standard deviations; CAH: congenital adrenal hyperplasia; FAH: functional adrenal hyperandrogenism; DHEAS: dehydroepiandrosterone sulfate.",
"     <br>",
"      * After obtaining an early morning blood sample for baseline steroid intermediates (eg, 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, dehydroepiandrosterone, androstenedione) and a 24-hour urine for corticoids (ie, free cortisol and 17&alpha;-hydroxycorticoids, as well as creatinine to control for completeness of collection), a dexamethasone androgen-suppression test (DAST) is performed. A rare consideration is (apparent) cortisone reductase deficiency: baseline urinary corticoids consist primarily of cortisone metabolites rather than cortisol metabolites, so 17&alpha;-hydroxycorticoid excretion is elevated, but cortisol excretion is normal.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       A long DAST is a definitive test. This consists of a four-day course of dexamethasone 0.5 mg four times daily prior to an early morning post-test blood sample on day five. A short DAST (sampling blood 4 hours after a single noon-time 0.5 mg dexamethasone dose) maximally suppresses total and free testosterone and 17-hydroxyprogesterone, but DHEAS and cortisol are not maximally suppressed in comparison to the four-day DAST.",
"       <br>",
"        &Delta; Normal androgen suppression in response to the four-day DAST is indicated in our laboratory (95% cut-off levels) by total testosterone &lt;28 ng/dL (1.0 nmol/L), free testosterone &lt;8 pg/mL (28 pmol/L), DHEAS &lt;40 mcg/dL (1.0 micromol/L) (&gt;75 percent fall), and 17-hydroxyprogesterone &lt;26 ng/dL (0.8 nmol/L).",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Normal corticoid suppression is indicated by serum cortisol &lt;1.5 &micro;g/dL (40 nmol/L) and urinary cortisol &lt;10 mcg (27 nmol) per 24 hours by the second day of dexamethasone administration.",
"         <br>",
"          &sect; If androgen excess is suppressed by dexamethasone, further evaluation with a cosyntropin (ACTH) stimulation test is indicated.",
"          <br>",
"           &yen; If androgen and cortisol are both not normally suppressed, Cushing syndrome and cortisol resistance should be considered. Poor suppression can also result from non-compliance with the dexamethasone regimen.",
"           <br>",
"            &Dagger; Subnormal suppression of testosterone (as well as androstenedione and 17-hydroxyprogesterone) and a normal suppression of cortisol and DHEAS is characteristic of PCOS, but the rare virilizing adrenal tumor or adrenal rests should be considered on the basis of clinical factors.",
"            <br>",
"             &dagger; The diagnosis of congenital adrenal hyperplasia (CAH) is suggested if the response to ACTH is &gt;5 SD above the average: for 17-hydroxyprogesterone this is &gt;1000 ng/dL (30 nmol/L) and for 17-hydroxypregnenolone &gt;5000 ng/dL (158 nmol/L).",
"             <br>",
"              ** Primary functional adrenal hyperandrogenism (FAH) (suggested by a modest rise in 17-hydroxypregnenolone or 17-hydroxyprogesterone that does not meet the criteria for the diagnosis of CAH) is sometimes the only demonstrable source of androgen excess in PCOS.",
"              <br>",
"               <font class=\"double_bullet\">",
"                &bull;&bull;",
"               </font>",
"               Idiopathic hyperandrogenism (distinct from idiopathic hirsutism) is the diagnosis when the source of hyperandrogenemia remains unexplained after intensive investigation (approximately 10 percent of cases). It often appears to be due to obesity.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005: 34:677.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_38_22127=[""].join("\n");
var outline_f21_38_22127=null;
